CA1341595C - Procedure for obtaining dna, rna, peptides, polypeptides, or proteins byrecombinant dna techniques - Google Patents

Procedure for obtaining dna, rna, peptides, polypeptides, or proteins byrecombinant dna techniques

Info

Publication number
CA1341595C
CA1341595C CA000617095A CA617095A CA1341595C CA 1341595 C CA1341595 C CA 1341595C CA 000617095 A CA000617095 A CA 000617095A CA 617095 A CA617095 A CA 617095A CA 1341595 C CA1341595 C CA 1341595C
Authority
CA
Canada
Prior art keywords
fact
procedure according
host cells
stochastic
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA000617095A
Other languages
French (fr)
Inventor
Marc Ballivet
Stuart Alan Kauffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1341595(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of CA1341595C publication Critical patent/CA1341595C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1093General methods of preparing gene libraries, not provided for in other subgroups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF] (urogastrone)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1048SELEX
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • C12N15/68Stabilisation of the vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Procedure for the production of peptides or polypeptides by microbiological means, characterized by the fact that genes which are at least partially composed of stochastic synthetic polynucleotides are produced simultaneously in a common milieu, that the genes thus obtained are introduced into host cells, that the independent clones of the transformed host cells containing these genes are simultaneously cultivated so as to clone the stochastic genes and lead to the production of proteins expressed by each of these stochastic genes, that screening and/or selection is carried out on such clones of transformed host cells in a manner to identify those clones producing peptides or polypeptides having at least one specified property, that the clones so identified are isolated, then grown in a manner so as to produce at least one peptide or polypeptide having the said property.

Description

MARC BALLIVET AND STUART KAUFFMAN

PROCEDURE FOR OBTAINING DNA, RNA, PEPTIDES, POLYPEPTIDES, OR PROTEINS BY RECOMBINANT DNA TECHNIQUES

This application is a division of our prior Canadian Patent Application Serial No. 504,653, filed March 20. 1986.

The present invention has as its object a procedure to obtain DNA, RNA, peptides, polypeptides or proteins, through use of transformed host cells containing genes capable of expressing these RNAs, peptides, polypeptides, or proteins: that is to say, by utilization of recombinant DNA techniques.
The invention aims at the production of stochastic genes or fragments of stochastic genes in a fashion to permit obtaining simultaneously, after transcription and translation of these genes, a very large number (on the order of at least 10.000) of completely new proteins or hybrids with known proteins, in the presence of host cells (bacterial or eucaryotic) containing the genes capable of expressing these proteins, and to carry out thereafter a selection or screen among the said clones, in order to determine which of them produce proteins with desired properties, for example structural, enzymatic, catalytic, antigenic. pharmacologic, or properties of liganding, and more generally, chemical, biochemical, biological, etc. properties. Thereafter the invention aims at improvement of the desired function by modification of the said stochastic genes, or modification of the products of the said genes.

The invention equally has as its aim procedures to obtain, and then improve, sequences of DNA or RNA with utilizable properties, notably chemical, biochemical, or biological properties.

It is clear, therefore, that the invention is open to a very large number of applications in very many areas of science, industry and medicine.

The procedure for production of peptides or polypeptides according to the invention is characterized in that one produces simultaneously, in the same medium, genes which are at least partially composed of synthetic stochastic polynucleotides, that one introduces the genes thus obtained into host cells, that one cultivates simultaneously the independent clones of the transformed host cells containing these genes in such a manner so as to clone the stochastic genes and to obtain the production of the proteins expressed by each of these stochastic genes, that one carries out selection and/or screening of the clones of transformed host cells in a manner to identify those clones producing peptides or polypeptides having at least one desired activity, that one thereafter isolates the clones thus identified and that one cultivates them to produce at least one peptide or polypeptide having the said property.
Where improvement of the desired property is sought, the procedure involves modification of the genes producing the identified peptides, followed by recloning the said genes, and selection or screening the
-2-transformed cells to identify those producing at least one peptide or polypeptide with improved function. It also includes rnodification of the protein product itself.

In a first means to utilize this procedure, stochastic genes are produced by stochastic copolymerization of the four kinds of deoxyphosphonucleoti des - A,C,G and T from the two ends of an initially linerized expression vector, foilowed by formation of cohesive ends In such a fashion as to form a stochastic first strand of DNA constituted by a molecule of expression vector possessing two stochastic sequences whose 3' ends are complementary, followed by the synthesis of the second strand of the stochastic DNA.

In a second mode to utiiize this procedure, stochastic genes are produced by copolymerization of oligonucleotides without cohesive ends, i n a manner to form fragments of stochast ic DNA, fol l owed by ligation of these fragments to a previously linearized expression v ector .

The expression vector can be a plasmid, notably a bacterial plasmid. Excellent results have been obtained using the plasmid pUC8 as the expression vector.

The expression vector can also be viral DNA or a hybrid of plasmid and viral DNA.

The host cells can be prokaryotic cells such as HB 101 and C 600, or eukaryotic cells.

When uti I iz ing the procedure according to the second mode mentioned above, it is possible to utilize ol igonucleotides which form a group of palindromic octamers.

Particularly good results are obtained by utilizing the following group of palindromic octamers:
5' GGAATTCC 3' 5' GGTCGACC 3' 5' CAAGCTTG 3' 5' C;!,TAJ GG 3' 5' CATCGATG 3' It is possible to use oligonucieotides which form a group of pal indromic heptamers.

Good results are obtained utifizing the following group of palindromic heptamers:
5' XTCGCGA 3' 5' XCTGCAG 3' 5' RGGTACC 3' where X= A, G, C, or T, and R A or T

According to a method to utilize these procedures which is particularly advantageous, one isolates and purifies the
-3- 13 4~595 transforming DNA of the plasmids from a culture of independent clones of the transformed host cells obtained by following the procedures above, then these plasmids are cut by at least one restriction enzyme corresponding to a specific restriction cutting site present in the palindromic octamers or heptamers but absent from the expression vector which was utilized; this cutting is followed by inactivation of the restriction enzyme, then one simultaneously treats the ensemble of linearized stochastic DNA
fragments thus obta i ned w i th T4 DNA I igase, i n such a manner to create a new ensemble of DNA containing new stochastic sequences, this new ensemble can therefore contain a number of stochastic genes larger than the number of genes in the initial ensemble.
One then utilizes this new ensemble of transforming DNA to transform the host cells and clone these genes, and finally utilizes screening and/ or selection and isolates the new clones of transformed host cells and finally these are cultivated to produce at least one pept i de or polypept i de, for example, a new protein, having a desired property.

Any other means to generate and clone stochastic DNA sequences so as to obtain their expression as novel peptides, polypeptides, or proteins, or their expression as the novel portion of a fusion protein, followed by screening or selection for a desired property and obtaining at least one clone producing a peptide with the desired property, can be used according to the Invention.

The property serving as the criterion for selection of the clones of host cells.can be the capacity of the peptides or polypeptides, produced by a given clone, to catalyse a given chemical reaction.
Further, for the production of several peptides and or polypeptides, the said property can be the capacity to catalyse a sequence of reactions leading from an initial group of chemical compounds to at least one target compound.

With the aim of producing an ensemble constituted by several or many peptides and or polypeptides which are reflexively autocatalytic, the said proprety can be the capacity to catalyse the synthesis of the same ensemble from amino acids and/ or ol igopeptides in an appropriate milieu.

The said property can also be the capacity to modify selectively the biological or chemical properties of a given compound, for example, the capacity to selectively modify the catalytic activity of a polypeptide.

The said property can also be the capacity to simulate, Inhibit, or modify at least one biological function of at least one biologically active compound, chosen, for example, among t;rE
hormones, neurotransmitters, adhesion factors, growth factors and specific regulators of DNA replication and/or transcription and/
or trans l at i on of RNA.

The said property can equally be the capacity of the peptide or polypeptide to bind to a given (igand.

-a- 4 1 5 9~-The Invention also has as its object the use of the peptide or polypeptide obtained by the procedures specified above, for the detection and/ or the titration of a ligand.

According to a particularly advantageous mode of utilization, the criterion for selection of the clones of transformed host cells is the capacity of these peptides or polypeptides to simulate or modify the effects of a biologically active molecule, for example, a protein; screening and/or selection for clones of transformed host cells producing at least one peptide or polypeptide having this property,is carried out by preparing or obtaining antibodies against the the active mol ecu I e, then uti I iz ing these antibodies after their purification, to identify the clones containing peptides or polypeptides which are bound by the said antibodies against the active molecule, then by cultivating the clones thus identified, separating and purifying the peptide or polypeptide produced by these clones, and finaliy by submitting the peptide or polypeptide to an in vitro assay to verify that it has the capacity to simulate or modify the effects of the said mol ecu I e.
The capacity to simulate or modify the effects of the said mol ecu i e by the stochast i c pept i de can be improved by modi f i cat i on of the gene coding for that peptide, retransformation of the host cells by the modified genes, and selection or screening for those modifications which improve the desired function. In addition, the said peptide can be modified chemicaliy, or derivatized, to improve its function.

According to this means to utilize the procedures according to the invention, the proper ty serving as the criterion of selection is that of havi ng at least one epitope s im i I ar to one of the epitopes of a given antigen.

The invention carries over to obtaining polypeptides by the procedure specified above and utilizable as chemotherapeutically active substances.

In particular, in the case where the said antigen is EGF, the invention permits obtaining polypeptides usable for chemotherapeutictreatment of epitheliomas.

The invention also appi ies to a use of the procedure specified above for the preparation of a vaccine; the application is characterized by the fact that antibodies against the pathogenic agent are i sol ated, for example anti bodi es formed after i njecti on of the pathogenic agent in the body of an animal capable of forminc antibodies against this agent, and these antibodies are used to identify the clones producing at least one protein having at least one epitope similar to one of the epitopes of the pathogenic agent, the transformed host cell corresponding to these clones are cultured to produce these proteins, this protein(s) is isolated and purified from the clones of cells, then this protein(s) is used for the production of a vaccine against the pathogenic agent. The identified proteins can, as above, be improved by modifications (eg. mutagenizing) of the stochastic genes coding for the said proteins, retransformation of those genes i nto appropriate host cei I s expressing the modi f ied 1341 a95 proteins, rescreening or selection of those with improved capacity to be bound by antibodies against the initial antigenic agent, and use of these improved proteins to produce a vaccine.

For example, in order to prepare an anti-HVB vaccine, one can extract and purify at least one capside protein of the HVB virus inject this protein into an animal capable of forming antibodies against this protein, recover and purify the antibodies thus formed, utilize these antibodies to identify the clones producing at least one protein having at least one epitope sim i I ar to one of the epitopes of the HVB virus, then cu l tivate the clones of transformed host cells corresponding to these clones in a manner to produce this protein(s), isolate and purify the protein(s) from the culture of these clones of cells and utilize the protein(s) for the production of an anti HVB vaccine.

According to a variant of the procedure, one identifies and isolates the clones of transformed host cells producing peptides or polypeptides having the property desired, by affinity chromatography against antibodies corresponding to a protein expressed by the natural part of the DNA hybrid.

For e;kample, in the case where the natural part of the hybrid DNA
contains a gene expressing B- galactosidase, one can advantageously Identify and isoiate the said clones of transformed host cells by affinity chromatography against anti B
galactosidase antibodies.

After expression and purification of hybrid peptides or polypeptides, one can separate and isolate their novel parts.
According to the invention, a means of utilizing the procedure is to screen or select for novel peptides polypeptides or proteins catalysing a given chemical reaction.

According to an advantageous means of utilizing the procedures according to the invention, the host cells consist in bacteria such as Escherichia coli whose genome contains neither the natural gene expressing B galactosidase, nor the EBG gene, that is to say, Z-,EBG- E coli. The tranformed cells are cultured in the presence of X gal and the indicator IPTG in the medium, and cells positive for B galactosidase functions are detected;
thereafter, the transforming DNA is transplanted into an appropriate clone of host cel I s for large scale culture to produce at least one peptide or polypeptide with B galactoasidase activity.

The property serving as the criterion for selection of the tranformed host cells can also be the capacity of the polypeptides or proteins produced by the culture of these clones to bind to a given compound.

This compound can be chosen advantagousely among peptides, polypeptides and proteins, notably among proteins regulating the transcription activity of DNA.

The invention has also as its object those proteins which are obtained in the case where the property serving as criterion of sel ecti on of the clones of transformed host cei 1 s consists in the capacity of these proteins to bind to regulatory proteins controlling transcription activity or replication of the DNA.

On the other hand, the said compound which is bound can also be chosen among DNA and RNA sequences.

The invention has,in addition, as an object obtaining a protein which is able to bind to DNA sequences which act as cis regulatory sequences controlling replication or transcription of neighboring DNA sequences, and by binding modify the transcription or replication of the neighboring DNA sequence. Equally the invention has as an object obtaining a protein which is able to bind to an RNA sequence and thereby control translation from that RNA or the stabiIity of the RNA.

The aim of the invention includes utilization of proteins obtained in the second case mentioned to modify the properties of transcription or replication of a sequence of DNA, in a cell containing the sequence of DNA, and expressing this protein.

The invention has as its object as weli a procedure to produce DNA, characterized by simultaneous production in the same medium, of genes at least partialiy composed of stochastic synthetic polynucleotides, that the genes thus obtained are introduced into host cel I s to produce an ensemb l e of transformed host cel 1 s, that screening and/or selection on this ensemble is carried out to i dent i fy those host ce l l s conta i n i ng stochast i c sequences of DNA
having at least one desired property , and finally, that the DNA
from the clones of host cells thus identified is isolated. The properties of the identified DNA can be improved by modification of the stochastic genes, eg through a variety of mutagenesis procedures known in themselves or described below, recioning into an appropriate vector, transformation of appropriate host cells, foi 1 owed by screen i ng or se i ect i on for an improved level of the desired property.

The invention also has as its object a procedure to produce RNA, characterized by simultaneous production in the same medium, of genes at least *partially composed of stochastic synthetic polynucleotides, that the genes thus obtained are introduced into host cells to produce an ensemble of transformed host cells, that the host cells so produced are cultivated simultaneously, and screening and/or selection of this ensemble is carried out in a manner to identify those host cells containing stochastic sequences of RNA having at least one desired property, and that the RNA be Isolated from the host cells thus identified. As above, the properties of the RNA thus Isolated can be Improved by modification of the corresponding stochastic genes, retransformation and reselection or rescreening.

The said property can be, the capacity to bind to a given compound, which might be for example a peptide or polypeptide or protein, or also the capacity to catalyse a given chemical reaction, or the capacity to be a transfer RNA.

In one aspect, the present invention provides a procedure for the production of peptides or polypeptides by microbiological means, characterized by the fact that genes which are at least partially composed of stochastic synthetic polynucleotides are produced simultaneously in a common milieu, that the genes thus obtained are introduced into host cells, that the independent clones of the transformed host cells containing these genes are simultaneously cultivated so as to clone the stochastic genes and lead to the production of proteins expressed by each of these stochastic genes, that screening and/or selection is carried out on such clones of transformed host cells in a manner to identify those clones producing peptides or polypeptides having at least one specified property, that the clones so identified are isolated, then grown in a manner so as to produce at least one peptide or polypeptide having the said property.

In another aspect, the present invention provides a method of detecting or titrating a ligand, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells: (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides: (d) screening said population of peptides or polypeptides for capacity to bind to a ligand; (e) contacting said peptide or polypeptide identified in step (d) with a sample suspected of containing said ligand. and (f) determining binding of said peptide or polypeptide to said ligand, wherein binding indicates the presence or amount of said ligand in said sample.

In yet another aspect, the present invention provides a method of inducing pharmacologic or chemotherapeutic action, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for capacity to selectively modify a chemical or biological property of a compound, and (e) contacting said peptide or polypeptide identified in step (d) with a sample suspected of containing said compound under conditions sufficient to selectively modify the chemical or biological effects of said compound.

In still yet another aspect, the present invention provides a method of diminishing the in vitro or in vivo concentration of antibodies specific for an antigen, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides: (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially ~-.

7a- 1341595 stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for at least one epitope similar to an epitope of an antigen, and (e) contacting said peptide or polypeptide identified in step (d) with a sample containing antibodies specific for said antigen under conditions sufficient for selective binding of said peptide or polypeptide and said antibodies.

In still yet another aspect, the present invention provides a method of preparing an agent for suppression of immunological hypersensitivity, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells;
(c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for capacity to selectively modify a chemical or biological property of a compound or for containing at least one epitope similar to an epitope of an antigen, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium to form an agent having immunological hypersensitivity suppression activity.

In still yet another aspect, the present invention provides a method of preparing an agent for inducing tolerance, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides;
(b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for containing at least one epitope similar to an epitope of an antigen, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium to form an agent having tolerance inducing activity.
In still yet another aspect, the present invention provides a method of preparing an agent for chemotherapeutic treatment of epitheliomas, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells;
(c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for at least one epitope similar to an epitope of an EGF antigen, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium to form an agent having chemotherapeutic action against epitheliomas.

In still yet another aspect, the present invention provides a method of producing a selective binding peptide, polypeptide, protein, DNA or RNA
composition, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said ;,,.,' 7b- 13415 95 population of at least partially stochastic synthetic polynucleotides into host cells; (c) expressing said population of at least partially stochastic synthetic polynucleotides to produce a population of peptides or polypeptides; (d) screening said population of peptides or polypeptides for capacity to bind to a compound, said compound comprising peptide, polypeptide, protein, DNA or RNA, and (e) combining said peptide or polypeptide identified in step (d) with a pharmaceutically acceptable medium.

In still yet another aspect, the present invention provides a procedure to produce DNA characterized by the fact that, in the same milieu, genes which are at least partially composed of stochastic synthetic polynucleotides are produced, that the genes so produced are introduced into host cells in a manner to produce an ensemble of transformed host cells, that these are grown so as to produce independent clones of the host cells so produced, that screening and/or selection is carried out on this ensemble to identify those host cells which contain those stochastic sequences of DNA having at least one desired property, and that such DNA is isolated from the identified cultures of the host cells.

In still yet another aspect, the present invention provides a method of modulating replication or transcription activity of a polynucleotide, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides; (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells;
(c) culturing said host cells to produce independent clones containing said at least partially stochastic synthetic polynucleotides; (d) screening said at least partially stochastic synthetic polynucleotides for capacity to bind to a peptide, polypeptide or protein regulating transcription or replication of DNA, and (e) linking said at least partially stochastic synthetic polynucleotide identified in step (d) with a sequence of DNA, wherein said at least partially stochastic synthetic polynucleotide provides a cis-regulatory sequence having the capacity to modulate transcription or replication of said DNA.

In still yet another aspect, the present invention provides a method of modulating the activity of a cis-regulatory sequence of replication or transcription, comprising: (a) synthesizing a population of at least partially stochastic synthetic polynucleotides: (b) introducing said population of at least partially stochastic synthetic polynucleotides into host cells; (c) culturing said host cells to produce independent clones containing said at least partially stochastic synthetic polynucleotides; (d) screening said at least partially stochastic synthetic polynucleotides for capacity to bind to a peptide, polypeptide or protein regulating transcription or replication of DNA, and (e) contacting said at least partially stochastic synthetic polynucleotides identified in step (d) with a sample containing said peptide, polypeptide or protein regulating transcription or replication of DNA
under conditions sufficient for selective binding, wherein said , ~õ.s 7c- 13-41595 selective binding of said at least partially stochastic synthetic polynucleotide modulates the transcription or replication activity of said peptide, polypeptide or protein.

In still yet another aspect, the present invention provides a procedure for the production of RNA, characterized by the fact that, in the same milieu, genes which are at least partially composed of synthetic stochastic polynucleotides are produced simultaneously, that the genes thus obtained are introduced in host cel l s in a manner to produce a n ensemble of transformed host cells, that the independent clones of transformed host cells so produced are grown simultaneously, that a screening and/or selection is carried out on this ensemble in a manner to identify those host cells which containing stochastic sequences of RNA having at least one desired property, and that the RNA is isolated from the cultures of host cells so identified.

First, we shall describe particularly useful procedures to carry out the synthesis of stochastic genes, and the introduction of those genes in bacteria to produce clones of transformed bacteria.

1) Direct synthesis on an expression vector.
a) Linearization of the vector.

30 micrograms, that is, approximately 1013 molecules of the pUC8 expression vector are linearized by incubation for 2 hours at 37 C with 100 units of the Pstl restriction enzyme in a volume of 300u1 of standard buffer for that enzyme. The linearized vector is treated with phenol-chloroform then precipitate in ethanol, taken up in a volume of 30 ul and loaded onto a 0.8% agarose gel in standard TEB buffer. After migration in a field of 3V/cm for three hours, the linearized vector is electro-eluted, precipitated in ethanol, and taken up in 30 ul of water.
b) Stochastic synthesis using the enzyme Terminal Transferase (TdT).

30 ug of the linearized vector are reacted with 30 units of TdT in 300 ul of the appropriate buffer, in the presence of 1mM dGTP, 1mM dCTP, 0.3 mM dTTP and 1 mM dATP. The lower concentration of dTTP is chosen in order to reduce the frequency of "stop" codons in the corresponding messenger RNA. A similar result, although somewhat less favorable, can be obtained by utilizing a lower concentration for dATP than for the other desoxynucleotide triphosphates. The progress of the polymerization on the 3' extremities of the Pstl sites is followed by analysis on a gel of aliquots taken during the course of the reaction.
When the reaction attains or passes a mean value of 300 nucleotides added per 3' extremity, it is stopped and the free nucleotides are separated from the polymer by differential precipitation or by passage over a column containing a molecular sieve such as Biogel*P60. After *Trade Mark :;ti T

7 d - 1 3 4 1 5 95 concentration by precipitation in ethanol, the polymers are subjected to a further polymerization with TdT, first in the presence of dATP, then in the presence of dTTP. These last two reactions are separated by a filtration on a gel and are carried out for short intervals (30 seconds to 3 minutes) in order to add sequentially 10-30 A followed by 10-30 T
to the 3' ends of the polymers.

c) Synthesis of the second strand of the stochastic DNA

Each molecule of vector possesses at the end of the preceeding operation, two stochastic sequences whose 3' ends are complementary.
The mixture of polymers is therefore incubated in conditions favoring hybridization of the complementary extremities st. ,~..

( 150mh1 NaCi , 10mM Tr i s-HCI , pH 7.6, 1 mN1 EDTA at 65 -C for 10 minutes, followed by lowering the temperature to 22 C at a rate of 3 to 4 C Per hour. The hybridized polymers are then reacted with 60 units of the large fragment (Kienow) of polymerase I, in the presence of the four nuc l eot i de tr i phosphates ( 200mh1) at 4 C for two hours. This step accomplishes the synthesis of the second strand from the 3' ends of the hybrid polymers. The molecules which result from this direct synthesis starting from linearized vector are thereafter utilized to transform competent cells.

d) Transformation of competent clones 100 to 200 ml of competent HB101 of C600 cells at a con.centration of 1010 cells/mi, are incubated with the stochastic DNA
preparation (from above) in the presence of 6mM CaC12, 6 mP-1 Tris-HCI pH8, 6 mP-i MgCl2 for 30 minutes at 0 C. A temperature shock of 3 minutes at 37 C is imposed on the mixture, followed by the addition of 400 to 800 ml of NZY culture medium, without ant i bi otics. The transformed cu l ture is Incubated at 37 C for 60 minutes, then diluted to 10 litres by addition of NZY medium containing 40 ug/ml of ampicillin. After 3 - 5' hours of incubation at 37 C, the amplified culture is centrifuged, and the pel I et of transformed cel I s i s lyophi lysed and stored at -70 C.
Such a culture contains 3 x 107' to 108, independent transformants, each containing a unique stochastic gene inserted into the expression vector.

II) Synthesis of stochastic genes starting from oligonucleotides w ithout cohesive ends.

This procedure is based on the fact that polymerization of judiciously chosen palindromic oligonucleotides permits construction of stochastic genes which have no "stop" codon in any of the six possible reading frames, whi l e at the same time assuring a balanced representation of triplets specifying all amino acids. Further, and to avoid a repetition of sequence motifs in the proteins which result while using only a small number of initial palindromic oligonucleotides, the oligonucleotides can contain a number of bases which is not a mul ti pi e of three. The example which fol I ows describes the use of one of the possible combinations which fulfil these criterio:

a) Choice of a group of octamers The group of oligonucleotides following:
5' GGAATTCC 3' 5' GGTCGACC 3' 5' CAAGCTTG 3' 5' CCATATGG 3' 5' CATCGATG 3' Is composed of 5 paiindromes ( thus self complementary sequences) where it is easy to verify that their stochastic polymerization does not generate any "stop" codons, and specifies all the amino acids.

Obviously, one can utlIize other groups of palindromic octamers which do not generate any "stop" codons and specify all the amino acids found in polypeptides. Clearly, it is also possible to utilize non palindromic groups of octamers, or other oligomers, under the condition that their complements forming double stranded DNA are also used. Further it is possible to use more than 5 pal indromic octomers.

b) Assembly of an ensemble stochastic genes from a group of octamer s.

A mixture containing 5 ug of each of the oligonucleotides indicated above ( previously phosphorylated at the 5' position by a standard procedure) are reacted in a 100 ul volume containing 1 mM ATP, 10% polyethYl enegiycol, and 100 un i ts of T4 DNA I igase in the appropriate buffer at 13 C for six hours. This step carries out the stochastic polymerization of the oligomers in the double stranded state and without cohesive ends. The resulting polymers are isolated by passage over a molecular sieve (Biogel P60) recovering those with 20 to 100 oiigomers. After concentration, th i s f ract i on is aga i n su bm i tte d to cata i y s i s of po l y mer i z at i on by T4 DNA I igase under the condi ti ons described above. Thereafter, as described above, those polymers which have assembled at least 100 oligomers are i soi ated.

c) Preparation of the host pl asmi d The pUC8 express i on vector is 1 i near i zed by the Smal enzyme in the appropriate buffer, as described 9.~ove. The vector linearized by SP4a I does not have cohesive ends. Thus the linearized vector is treated by calf intesting alkaline phosphatase (CIP) at a level of one unit per microgram of vector in the appropriate buffer, at 37 C for 30 minutes. The CIP enzyme is thereafter inactivated by two successive extractions with phenol-choloform. The linearized and dephosphorylated vector is precipitated in ethanol, then redissolved in water at 1 mg/mI.

d) Ligation of stochastic genes to the vector Equimolar quantities of vector and polymers are mixed and incubated in the presence of 1000 un i ts of T4 DNA I igase, 1 mM
ATP, 10% polyethylene glycol, in the appropriate buffer, for 12 hours at 13 C. This step ligates the stochastic polymers in the expression vector and forms double stranded circular molecules which are, therefore, capable of transforming.

Transformaticn of competent clones.

Transformation of competent clones is carried out in the manner previously described.

III) Assembly of stochastic genes starting from a group of heptamers.

This procedure differs from that just discus$ea in that it utilizes palindromic heptamers have variable cohesive ends, In place of the octamers. This has the advantage of allowing assembly of stochastic sequences containing a smaller number of identical mo1-ifs.

a) Choice of a group of heptamers It is possible, as, an example, to use the following three palindromic heptamers:

5' XTCGCGA 3' 5' XCTGCAG 3' 5' RGGTACC 3' where X = A,G,C or T and R = A or T, and where polymerization cannot generate any "stop" codons and forms triplets specifying all the amino acids.

Clearly it is possible to use other groups of heptamers fulfill ing these same conditions.

b) Polymerization - of a group of heptamers This polymerization is carried out exactly in the fashion described above fcr octamers.

c) Elimination of cohesive extremities The polymers thus obtained have one unpaired base on their two 5' extremities. Thus, It is necessary to add the complementary base to the corresponding 3' extremities. This is carried out as follows: 10 micrograms of the double stranded polymers are reacted with 1 0 un i ts of the Klenow enzyme, i n the presence of the four deoxynuc l eot i de- phosphates (200 mM) in a volume of 100 ul, at 4 C, for 60 minutes. The enzyme is inactivated by phenol chloroform extraction, and the polymers are cleansed of the residual free nucleotides by differential precipitation. The polymers are then ligated to the host plasmid (previously linearized and dephosphorylated) by following the procedures described above.

It is to be noted that the two last procedures which were described utilize palindromic octamers or heptamers which constitute specific sites of certain restriction enzymes. These sites are absent, for the most part, from the pUC8 expression vector. Thus, it is possible to augment considerably the complexity of an initial preparation of stochastic genes by proceeding In the following way: The plasmid DNA derived from the culture of 10 7 independent transformants obtained by one of the two last procedures described above, i s i so I ated. After th i s DNA
is purified, it Is partially digested by the CIa I restriction enzyme (procedure II) or by the Pst I restriction enzyme (procedure 111). After inactivation of the enzyme, the partially digested DNA is treated with T4 DNA I igase, which has the effect of creating a very large number of new sequences, whi l e conserving 1~4 1595 -1,-the fundamental properties of the initial sequences. This new ensemble of stochastic sequences can then be used to transform competent cells.

In addition, the stochastic genes cloned by procedures 11 and 111 can be excised intact from the pUC8 expression vector by utilizing restriction sites belonging to the cloning vector and not represented in the stochastic DNA sequences.

Recombination within the stochastic genes generated by the two procedures just described, which results from the internal homology due to the recurrent molecular motifs, is an important additional method to achieve in vivo mutagenesis of the coding sequences. This results in an augmentation of the number of new genes which can be examined.

Finally, for all the procedures to generate novel synthetic genes, it Is possible to use a number of common techniques to modify genes i n vivo or in v i tro, such as a change of reading frame, inversion of sequences with respect to their promoter, point mutations, or utilization of host cells expressing one or several suppressor tRNAs.

In considering the above description, It is clear that it is possible to construct, in vitro, an extremely large number ( for example greater than a billion) different genes, by enzymatic polymerization of nucleotides or of oligonucleotides. This polymerization is carried out in a stochastic manner, as determined by the respective concentrations of the nucleotides or oligonucleotides present in the reaction mixture.

As indicated above, two methods can be utiiized to clone such genes (or coding sequences): the polymerization can be carried out directly on a cloning expression vector, which was previously linearized; or it is possible to proceed sequentially to the polymerization then the ligation of the polymers to the expression v ector .

In the two cases, the next step is transformation or transfection of competent bacteriaf cells (or cells in culture) . This step const i tutes cl on i ng the stochast i c genes in I iv i ng cel i s where they are indefinitely propagated and expressed.

Clearly, in addition to the procedures which were described above, it is feasible to use all other methods which are appropriate for the synth esis of stochastic sequences. In particular, It is possible to carry out polymeriza tion, by biochemical means, of single stranded oligomers of DNA or RNA obtained by chemical synthesis, then treat these segments of DNA or RNA by establ i shed procedures to generate double stranded DNA (cDNA) in order to clone such genes.

Screening or selection of clones of transformed host cells The final step of the procedure according to the invention consists in examining the transformed or transfected cells by selection or screening, in order to isolate one or several cells whose transform i ng or transfecting DNA leads to the synthesis of a transcription product (RNA) or translation product (protein) having a desired property. These properties can be, for example, enzymatic, functional, or structural.

One of the most important aspects of the procedure, according to the invention, is that it permits the simultaneous screening or selection of an exploitable product (RNA or protein) and the gene which produces that product. In addition, the DNA synthesized and cloned as described, can be selected or screened in order to isolate sequences of DNA constituting products in themselves, having exploitable biochemical properties.

We shali now describe, as non-limitating examples, preferred procedures for screening or selection of clones of transformed cells such that the novel proteins are of interest from the point of view of industrial or medical applications.

One of these procedures rests on the idea of producing, or obtaining, polyclonai or monoclonal antibodies, by established techniques, directed against a protein or another type of mol ecu I e of biochemical or medical interest, where that molecule is, or has been rendered, immunogenic, and thereafter using these ant kodi es as probes to i dent i fy among the very large number of clones transformed by stochastic genes, those whose protein react with .. these antibodies.. This reaction is a re-sult of a structural (epitope) homology which exists between the polypeptide synthesized by the stochastic gene and the initial molecule. It is possible in this way to isolate numbers of novel proteins with molecular features similar to the epitopes or antigenic determinants on the initial molecule. Such novel proteins are candidates to simulate, stimulate, modulate, or block the effect of the initial molecule. It should be clear that this means of selection or screening can have very many pharmacologic and biomedical applications. As noted above, the peptides identified as having epitopes similar to the initial molecule of Interest can be improved by modifying the stochastic genes coding for the said i dent i f i ed prote i ns or pept i des, fol l owed by recloning and rescreening, or derivitization of those peptides themselves by known procedures.

Below we describe, as a non limiting example, this first mode of operation in a concrete case:

EGF, (epidermal growth factor) is a small protein present in the blood, whose role is to stimulate the growth of epithelial cells.
This effect is obtained by the interaction of EGF with a specific receptor situated in the membrane of epithelial cells. Prepare antibodies directed against EGF by injecting animals with EGF
coupled to KLH (keyhofe Iimpet hemocyanin) to augment the Immunogenecity of the EGF. The anti-EGF antibodies of the immunized animals are purified, for example, by passage over an affinity column, where the I igand is EGF or a synthetic peptide corresponding to a fragment of EGF. The purified anti-EGF
antibodies are then used as probes to screen a large number of bacterial clones lysed by chloroform and on a solid support. The anti-EGF antibodies bind those stochastic peptides or proteins whose epitopes resemble those of the initial antigen. The clones containing such peptides or proteins are shown by autoradiography after i ncubati on of the sol i d support with radioactive protein A, or after incubation with a radioactive anti-antibody antibody.
These steps identify those clones, each of which contains one protein (and its gene) reacting with the screening antibody. It is feasible to screen among a very large number of colonies of bacterial cells or viral plaques (for example, on the order of 1,000,000) and it is feasible to detect extremely small quantities, on the order of 1 nanogram, of protein product.
Thereafter, the i dentif ied clones are cu I tur ed and the proteins so detected are purified In conventional ways. These proteins are tested in vitro in cultures of epithel ial cells to determine if they i nhi bi t, - simulate, or modu I ate the effects of EGF on these cultures. Among the proteins so obtained, some may be utilized for the chemoihirageutic treatment of epitheliomes. The activities of the proteins thus obtained can be improved by mutation of the DNA coding for the proteins, in ways ana I ogous to those descr i bed above, or by derivitizing the proteins identified.

A vzr i ant of _th i s procedure cons i sts in puri fy i ng these stochast i c peptides, polypeptides or proteins, which have epitopes or molecular features causing them to be bound by antibodies against some antigens, for example antigens of a pathogen, and then utilizing the identified peptides as vaccines or more generally utilizing them to confer an immunity against a pathogenic agent or to exercise other effects on the immunological system, for example, to create a tolerance or diminish hypersensitivity with respect to a given antigen, in particular due to binding of these peptides, polypeptides or proteins with the antibodies directed against this antigen. It is clear that it Is possible to use such peptides, polypeptides or proteins In vitro as well as in vivo.
More precisely, in the ensemble of novel proteins which react with the antibodies against a given antigen X, each has at least one epitope in cormon with X, thus the ensemble has an ensemble of epitopes in common with X. This permits utilization of the ensemble or sub-ensemble as a vaccine to confer immunity against X. It i s, for example, easy to purify one or several of the capsid proteins of the hepatitis B virus. These proteins can then be injected into an animal, for example, a rabbit, and the antibodies corresponding to the initial antigen can be recovered by affinity column purification. These antibodies may be used, as described above, to identify clones producing at least one protein having an epitope resembling at least one of the epitopes of the Initial antigen. After purification, these proteins are used as antigens (either alone or In combination) with the aim of confering protection against hepatitis B. The final production of the vaccine does not require further access to the initial pathogenic agent. Nor is it required that the initial antigens derived from the hepatitis 8 virus be protein antigens, rather they mlght include Polysaccharide or other antigenic determinants.
Further, in favorable cases, no access to the.initial pathogen is needed, rather the high titre circulating antibodies against the pathogen derived from an animai or human exposed to the pathogen can be used as the initial step to screen for peptides bound by those high titre antibodies. Such high titre circulating antibodies can reach 1p to 10% of all circulating antibodies, hence tp - 10% of the stochastic peptides or polypeptides identified as crossreacting will have antigenic determinants similar to the (perhaps unknown) pathogen. This mixture of identified cross reacting peptides can be used as a vaccine. Or the subset of peptides cross reacting with the high titre antibody molecules can be selected by screening the set of cross reacting peptides with the serum, and identifying those peptides to which a high level of circulating antibody is present in the serum. This selected set of cross reactino peptides may then be used with the a i m of produc i ng a vacc i ne conf er i ng i mmun i ty, or as agents w i th other immuno-modifying actions.

Note that, during the description of the procedures above, a number of means to achieve selection or screening have been described. All these procedur.es may require the purification of a particular protein from a transformed clone. These protein purifications can be carried out by established procedures and utilize, in particular, the techniques of gel chromatography, by ion exchange, and by affinity chromatography. In addition, the proteins generated by the stochastic genes can have been cloned in the form of hybrid proteins having, for example, a sequence of the B - galactosidase enzyme which permits affinity chromatography against anti - B-galactosidase antibodies, and allows the subsequent cleavage of the hybrid part ( that is to say, allowing separation of the novel part and the bacterial part of the hybrid protein.

Below we describe the principles and procedures for selection of peptides or polypeptides and the corresponding genes, according to a second method of screening or selection based on the detection of the capacity of these peptides or polypeptides to catalyse a speci f ic reaction.

As an concrete and non Iimiting example, screening or selection in the particular case of proteins capable of catalysing the cleavage of lactose, normally a function fulfilled by the enzyme B-galactosidase (B-gal) will be described.

As noted above, the first step of the procedure consists in generating a very large ensemble of expression vectors, each express i ng a di st i nct novel protein. To be concrete, for example, choose the pUC8 expression vector with cloning of stochastic sequences of DNA In the Pst I restriction site. The plasmids thus obtained are then introduced In a clone of E coii from whose genome the natural gene for B-galactosidase, Z,and a second gene EBG , unrelated to the first but able to mutate towards B -gal function, have both been eliminated. Such host cells (Z-,EBG-) are not able by themselves to hydrolyse lactose, and as a consequence to use lactose as a carbon source for growth. This permits uti I ization of such host clones for screen i ng or seI ecti on for B-gal function.

A.':.cosi;venientbiological assay to analyse transformed E coll clones for those which have novel genes expressing a B gal functions consists in the culture of bacteria transformed as described In petri dishes containing X-gal in the medium. In this case, all bacterial colonies expressing a B gal function are visualized as blue colonies. By using such a biological assay, it is possible to detect even weak catalytic activity. The specific activity of characteristic enzymes ranges from 10 and 10,000 product molecules per second.

Supposing that a protein synthesized by a stochastic gene. has a weak specific acitivity, on the order of one molecule per 100 seconds, it remains possible to detect such catalytic activity.
In a petri dish containing X-gal in the medium, and in the presence of the non metabolizable inducer IPTG (isopropyl-D-thio galactoside) visualization of a blue region requires cleavage of about 1010 to 1011 molecules'of X gal per square millimeter. A
bacterial colony expressing a weak enzyme and occupying a surface area of 1n,m2. has about 107 to 108 cells. If each cell has only one copy of the weak enzyme, each cell would need to catalyse cleavage of between 10,000 and 100 of X gal to be detected, which would require beween 2.7 and 270 hours. Since under selective conditions it is possible to am plify the number of copies of each plasmid per cell to 5 to 20 copies per cell, or even to 100 or 1000, and because up to 10% of the protein of the cell can be specified by the new gene, the duration needed to detect a colony b I ue in the case of 100 enzyme mol ecu 1 es of weak act i v i ty per ce I I
is on the order of 0.27 to 2.7 hours.

As a consequence of these facts, screening a very large number of independent bacterial colonies, each expressing a different novel gene, and using the capacity to express a B gal function as the selection criterion, is fully feasible. It is possible to carry out screening of about 2000 colonies in one Petri dish of 10 cm diameter. Thus, about 20 miliion colonies can be screened on a sheet of X gal agar 1 square meter.

It is important to note that bacterial colonies which appear blue on X gal Petri dishes might be false positives due to a mutation in the bacterial genome which confers on It the capacity to metabol ise lactose, or fer other reasons than those which result fran a catalytic activity of the novel protein expressed by the cells of the colony. Such false positives can be directly eliminated by purifying the DNA of the expression vector from the positive colony, and retransforming Z-, EBG- E coli host cells.
If the B gal activity is due to the novel protein coded by the new gene in the expression vector, all those cells transformed by that vector will exhibit B gal function. In contrast, if the initial blue colony Is due to a mutation In the genome of the host cell, it is a rare event and independent of the transformation, thus the number of cel I s of the new clone of transformed E coil capable of expressing B gaI function will be small or zero.

The power of mass simultaneous purification of all the expression vectors from all the positive clones (blue) followed by retransformation of naive bacteria should be stressed. Suppose that the aim Is to carry out a screening to select proteins having a catalytic function, and that the probability that a new peptide or polypeptide carries out this function at least weakly is 10-6 while the probability that a clone of the E coli bacterial host undergoes a mutation rendering it capable of carrying out the same function is 10`5 , then it can be calculated that among 20 million transformed bacteria which are screened, 20 positive clones will be attributable to the novel genes in expression vectors which each carries, while 200 positive clones will be the result of genomic mutation. Mass purification of the expression vectors from the total of 220 positiv e bacterial clones followed by retransformation of naive bacteria with the mixture of these express i on vectors w i l l produce a large number of pos i tive clones consisting of all those bacteria transformed with the 20 expression vectors which code for the novel proteins having the desired function and a very small number of bacterial clones resulting from genomic mutations and containing the 200 expression vectors which are not of interest. A small number of cycles of purification of expression vectors from positive bacterial colonies, followed by such retransformation, allows the detection of very rare expression vectors truely positive for a desired catalytic-ractivity despite a high background rate of mutations in the host cells for the same function.

Following screening operations of this type, it is possible to purify the new protein by established techniques. The production of that protein in large quantity is made possible by the fact that identification of the useful protein occurs together with slmuitaneous identificatlon of the gene coding for the same protein. Consequently, either the same expression vector can be used, or the novel gene can be transplanted into a more appropriate expression vector for its synthesis and isolation in large quantity.

It is feasible to apply this method of screening for any enzymatic function for which an appropriate biological assay exists. For such screenings, it is not necessary that the enzymatic function which is sought be useful to the host cell. It is possible to carry out screenings not only for enzymatic functions, but for any other desired property for which it Is possible to establish an appropriate biological assay. Further, it Is feasible to carry out, even In the simple case of B - gal function visualized on an X-gal Petri piate, a screening of on the order of 100 million, or even a billion novel genes for that cataiytic activity or other desired property.

Selection of transformed host cel i s.

On the other hand, It Is possible to use selection techniques for any property, catalytic or otherwise, where the presence or absence of the property can be rendered essential for the survival of the host cells containing the expression vectors which code for the novel genes, or also can be used to select for those viruses coding and expressing the desired novel gene. As a non-limiting, but concrete example, selection for B galastosidase function shall be described. An appropriate clone of Z-EBG- E. coli is not able to grow on lactose as the sole carbon source. Thus, after carrying out the first step described above, it is possible to culture a very large number of host cells transformed by the expression vectors coding for the novel genes, under selective conditions, either progressive diminution of other sources of carbon, or utilization of Iactose alone from the start. During the course of such selection, In vivo mutagenesis by recombination, or by explicitly recovering the expression vectors and mutagenizing their novel genes in vitro by various mutagens, or by any other common tech n i que, perm i ts adapt i ve improvements in the capacityto fulfil the desired catalytic function. When both selection techniques and convenient bioassay techniques exist at the same time, as in the present case, it is possible to use selection techniques initially to enrich the representation of host bacteria expressina the B - gal function, then carry out a screening on Petri-plateson X-gal medium to establish efficiently which are the positive cells. In the absence of convenient bieassays, appl ication of progressively stricter selection is the easiest route to purify one or a small number of distinct host cells whose expression vectors code for the proteins catalysing the desired reaction.

It is possible to utilize these techniques to find novel proteins having a large variety of structural and functional characteristics beyond the capacity to catalyse a specific reaction. For example, it is possible to carry out a screen or select for novel proteins which bind to ci s-regul atory sites on the DN A and thereby block the expression of one of the host cellI s functions, or block transcription of the DNA, stimulate transcription, etc.

For example, in the case of E. Coli, a clone mutant in the repressor of the lactose operon (I-) expresses B gal function constitutively due to the fact the lactose operator is not repressed. All cells of this type produce blue clones on Petri plates containing X-gal medium. It is possible to transform such host cells with expression vectors synthesizing novel proteins and carry out a screen on X-gal Petri plates in order to detect 1-hose clones which are not blue. Among those, some represent the case where the new protein binds to the lactose operator and represses the synthesis of B-gal. It is then feasible to mass isolate such plasmids, retransform, i- hosts isolate those clones which do not produce B-gal, and thereafter carry out a detailed verification.
As mentioned above, this procedure can be utilized in order to create then isolate, not only exploitable proteins, but also RNA
and DNA as products In themselves, having exploitable properties.
This results from the fact that, on one hand, the procedure consists in creating stochastic sequences of DNA which may interact directly with other cellular or biochemical constituents, and on the other hand, these sequences cloned In expression vectors are transcribed Into RNA which are themselves capable of multiple biochemical interactions.

-~ 8-An example of the use of the procedure to create and select for a DNA which is useful in itself.

This example illustrates selection for a useful DNA, and the purification and study of the mechanism of action of regulatory proteins which bind to the DNA. Consider a preparation of the oestradiol receptor, a protein obtained by standard techniques. In the presence of oestradiol, a steroid sexual hormone, the.
receptor changes conformation and binds tightly to certain specific sequences in the genomic DNA, thus affecting the transcription of genes implicated In sexual differentiation and the control of fertility. By incubating a mixture containing oestradiol, its receptor, and a large number of different stochastic DNA sequences inserted in their vectors, fol I owed by filtration of the mixture across a nitro cellulose membrane, one has a direct selection for those stochastic DNA sequences binding to the oestrogen-receptor complex, where only those DNAs bound to a protein are retained by the membrane. After washing and elution, the -DNA liberated from the membrane is utilized to transform bacteria. After culture of the transformed bacteria, the vectors which they contain are again purified and several cycles of i ncubat i on, f i I trat i on and transf ormat i on are carr i ed out as described above. These procedures allow the isolation of stochastic sequences of DNA having an elevated affinity for the oestradiol-receptor complex. Such sequences are open to numerous diagnostic and pharmacologic applications, in particular, for testing synthetic estrogens for the control of fertility and treatment of sterility.

Creation and selection of an RNA useful in Itself Let there be a large number of stochastic DNA sequences, produced as has been described and cloned in an expression vector. It follows that the RNA transcribed from these sequences in the transformed host cells can be useful products in themselves. As a non limiting example, it Is possible to select a stochastic gene coding for a suppressor transfer RNA (tRNA) by the following procedure:

A large number (> 103 ) of stochastic sequences are transformed into competent bacterial hosts carrying a "nonsense" mutation in the arg E. gene. These transformed bacteria are plated on minimal medium without argenine and with the selective antibiotic for that plasmid (ampicillin if the vector is pUC8). Only those transformed bacteria which have become capable of synthesizing arginine will be able to grow. This phenotype can result either f rom a back mutation of the host genome, or the presence i n the cell of a suppressor tRNA. It is easy to test each transformed colony to determine if the arg+ phenotype is or Is not due to the presence of the stochastic gene in Its vector; it suffices to purify the plasmid from this colony and verify that it confers an Arg+ phenotype on all arg E cells transformed by it.

Selection of proteins capable of catalysing a sequence of reactions.
Below we describe another means of selection, open to independent appi icati ons, based on the pri nci pl e of simultaneous and paral I el selection of a certain number of novel proteins capable of catalysing a connected sequence of reactions.

The basic idea of this method is the following: given an initial ensemble of chemical compounds considered as building blocks or elements of construction from which it is hoped to synthesize one or several desired chemical compounds by means of a catalysed sequence of chemical reactions, there exists a very large number of reaction routes which can be partially or completely substituted for one another, which are all thermodynamically possible, and which lead from the set of building blocks to the desired target compound(s). Efficient synthesis of the target compound is favored if each step of at least one react i on pathway leading from the building block compounds to the target compound is comprised of reactions each of which is catalysed. On tne other hand, it is relatively less important which among the many independent or partially Independent reaction pathways is catalysed. In the previous description, we have shown how it is poss i b l e to obta i n a very large number of host ce I I s each of wh i ch expresses a di st i nct novel protein.

Each of these novel proteins is a candidate to catalyse one or another of the possible reactions,in the set of all the possible reactions leading from the ensemble of building blocks to the target compoun d(s ) . I f a suf f i c i ent l y large number of stochast i c proteins is present in a reaction mixture containing the building b I ock compounds, such that a suf f i c i ent-l y large number of the possible reactions are catalysed, there is a high probability that one connected sequence of reactions leading from the set of building block compounds to the target compound will be catalysed by a subset of the novel proteins. It Is clear that this procedure can be extended to the catalysis not only of one, but of several target compounds simultaneously.

Based on this principle it is possible to proceed as follows in order to select in parallel a set of novel proteins catalysing a desired sequence of chemical reactions:

1. Specify the desired set of compounds constituting the building blocks, utilizing preferentially a reasonably large number of distinct chemical species in order to increase the number of potential concurrent reactions leading to the desired target compound(s).

2. Using an appropriate volume of reaction medium, add a very large number of novel stochastic proteins isolated from transformed or transfected cells synthesizing these proteins.
Carry out an assay to determine i f the target compound is formed.
If it is, confirm that this formation requires the presence of the mixture of novel proteins. If so, then then the mixture should contain a subset of proteins catalysing one or several reaction pathways leading from the building block set to the target compound. Purify and divide the initial ensemble of clones which synthesize the set of novel stochastic proteins. Thereafter, retest the subset to see If is able to catalyse the sequence of reactions leading to the target compound.

More precisely, as a non I imiti ng example, below we describe selection of a set of novel proteins capable of catalysing the synthesis of a specific small peptide, In particular, a pentapeptide, starting from a building block set constituted of smaller peptides and amino acids. All peptides are consistuted by a I inear sequence of 20 different types of amino acids oriented from the amino to the carboxy terminus. Any peptide can be formed in a single step by the terminal condensation of two smaller peptides (or of two amino acids), or by hydrolysis of a larger peptide. A peptide with M residues can thus be formed by M- 1 condensation reactions. The number of reactions, R, by which a set of peptides having lengths 1,2,3...M residues can be interconverted is larger than the number possible molecular species, T. This can be expressed as R/T = M - 2. Thus, starting from a given ensemble of peptides, a very large number of independent or partially independent reaction pathways lead to the synthesis of a specific target peptide. Choose a pentapeptide whose presence can be determined conveniently by some common assay technique for example HPLC (liquid phase high pressure chromatography), paper chromatcfgraphy,' etc. Formation of a peptide bond requires energy in a dilute aqueous medium, but if the peptides participating In the condensation reactions are adequately concentrated, formation of peptide bonds is thermodynamically favored over hydrolysis and occurs efficiently in the presence of an appropriate enzymatic catalyst, for example pepsin or trypsin, without requiring the presence of ATP or other high energy compounds. Such a reaction mixture of small peptides, whose amino acids are marked radioactively to act as tracters with 3H, 14C,35S, constituting the building block set can be used at suff icientlyhigh concentrations to lead to condensation reactions.
For example, it is feasible to proceed as follows: 15 mg of each amino acid and small peptides having 2 to 4 amino acids, chosen to constitute the building block set, are dissolved in a volume of 0.25m1 per 1.0 ml of a 0.1 M pH 7.6 phosphate buffer. A large number of novel proteins, generated and isolated as described above are purified from their bacterial other host cells. The mixture of novel proteins is dissolved to a final concentration on the order of 0.8 to 1.0 mg/mI in the same buffer. 0.25 ml to 0.5 ml of the protein mixture is added to the mixture of building blocks. This is incubated at 25"C to 40 C for 1 to 40 hours.
Al iquots of 8 ul are removed at regular i nterval s, the first i s used as a "blank" and taken before addition of the mixture of novel proteins. These aliquots are analysed by chromatography using n-butanol-acetic acid-pyridine-water (30:6:20:24) as the solvent. The chromatogram is dried, and analysed by ninhydrin or autoradlography (with or without intensifying screens). Because the compounds constituting the building block set are radioactively marked, the target compound w i I I be radioactive and It will have a specific activity high enough to permit detection ~341595 at the level of 1 - 10 ng. In place of standard chromatographic analysis, it is possible to use HPLC (high pressure liquid chromatography) which is faster and simpler to carry out. INore generally,all the usual analytic procedures can be employed.
Consequently it Is possible to detect a yield of the target compound(s) of less than one part per million by weight compared to the compounds used as Initial building blocks.

If the pentapeptide is formedin the conditions described above, but not when an extract is utilized which is derived from host cells transformed by an expression vector containing no stochastic genes, the formation of the pentapeptide is not the result of bacterial contaminants and thus requires the presence of a subset of the novel proteins in the reaction mixture.

The following step consists in the separation of the particular subset of cells which contain expression vectors with the novel proteins catalysing the sequence of reactions leading to the target pentapeptide. As an example, if the number of reactions forming this sequence is 5, there are about 5 novel proteins which catalyse the necessary reactions. If the clone bank of bacteria containing the expression vectors which code for the novel genes has a number of distinct novel genes which is on the order of 1,000,000, aiI these expression vectors are isolated en masse and retransformed into 100 distinct sets of 108 bacteria at a ratio of vectors to bacteria which is suff ici ently low that, on average, the number of bacteria in each set which are transformed is about half the number of initial genes, ie about 500,000.
Thus, the probability that any given one of the 100 sets of bacteria contains the entire set of 5 critical novel proteins Is (1/2)5 = 1/32. Among the 100 initial sets of bacteria, about 3 will contain the 5 critical transformants. In each of these sets, the total number of new genes Is only 500,000 rather than 1,000,000. By successive repetitions the total number of which is about 20 in the present case, this procedure isolates the 5 critical novel genes. Following this, mutagenesis and selection on this set of 5 stochastic genes allows improvement of the necessary catalytic functions. In a case where it is necessary to catalyse a sequence of 20 reactions, and 20 genes coding novel proteins need to be isolated in parallel, it suffic er, to adjust the mul ti pi icity of transformation such that each set of 108 bacteria receives 80% of the 10e6 stochastic genes, and to use 200 such sets of bacteria. The E robability that all 20 novel proteins are found in one set is 0.82 = 0.015. Thus, about 2 among the 200 sets will have the 20 novel genes which are needed to catalyse the formation of the target compound. The number of cycles required for i sol at i on of the 20 novel genes i s on the order of 30.

The principles and procedures described above generalize from the case of peptides to numerous areas of chemistry in which chemicai reactions take place in aqueous medium, In temperature, pH,and concentration conditions which permit general enzymatic function.
In each case it is necessary to make use of an assay method to detect the formation of the desired target compund(s). It is also necessary to chose a suf f i c i ent l y large number of bu i l d i ng b l ock compounds to augment the number of reaction sequences which lead to the tareget compound.

The concrete example which was given for the synthesis of a target pentapeptide can also be generalized as follows:

The procedure as described, generates among other products, stochastic peptides and proteins. These peptides or proteins can act, catalytically or in other ways, on other compounds. They can equally constitute the substrates on which they act. Thus, it is possible to select (or screen) for the capacity of such stochast i c pept i des or prote i ns to interact among themse I ves and thereby modify the conformation, the structure or the function of some among them. Similarly , it is possible to select (or screen) for the capacity of these peptides and proteins to catalyse among themselves, hydrolytic, condensation, transpeptidation or other reactions modifying the peptides. For example, the hydroiyisis of a g i ve stochast i c pept i de by at least one member of the set of stochast i c pept i des and prote i ns can be fol l owed and measured by radi cactive marking of the given protein fol l owed by an i ncubati on w i th a mix.ture-of the stochast i c prote i ns i n the presence of ions such as Mg,Ca,Zn, Fe and ATP or GTP. The appe-arance of radioactive fragments of the marked protein i s measured as described. The stochastic protein(s) which catalyse this reaction can aaain be isolated, along with the gene(s) producing them, by sequential diminution of the I ibrary of transformed clones, as described above.

An extension of the procedure consists in the selection of an ensemble of stochastic peptides and polypeptides capable of catalysing a'set of reactions leading from the initial building blocks (amino acids and small peptides) to some of the peptides or polypeptides of the set. It Is therefore also possible to select an ensemble capable of catalysing its own synthesis; such a ref l ex i veiy autocata lyt i c set can be estab l i shed i n a chemostat where the products of the reactions are constantly diluted, but where the concentration of the bu i I di ng blocks are mai ntai ned constant. Alternatively, synthesis of such a set is aided by encl os i ng the complex set of pept i des in t i posomes by standard techniques. In a hypertonic aqueous environment surrounding such I iposomes, condensation reactions formina larger peptides lowers the osmotic pressure inside the I iposomes, drives water molecules produced by the condensation reactions out of the Iiposomes, hence favors synthesis, of larger polymers. Existence of an autocatalytic ensemble can be verified by two dimensional gel electrophoresis and by HPLC, showing the synthesis of a stable distribution of peptides and polypeptides. The appropriate reaction volume depends on the number of molecular species used, and the concentrations necessary to favor the formation of peptide bonds over the i r hydrolys i s. The di str i but i on of mol ecu l ar species of an autocatalytic ensemble is free to vary or change due to the emergence of variant autocatalytic ensembles. The peptides arid polypeptides which constitute an autocataly tic set may have certain elements 1 n common with the large initial ensemble (consitituted of coded peptides and polypeptides as given by our procedure) but can also contain peptides and polypeptides which are not coded by the ensemble of stochastic genes coding for the Initial ensemble of peptides and proteins.

The set of stochastic genes whose products are necessary to establish such an autocatalytic set can be Isolated as has been described, by sequential diminution of the library of transformed clones. In addition, an autocatalytic set can contain coded peptioes initially coded by the stochastic genes and synthesized continuously in the autocatalytic set. To isolate this coded subset of peptides and proteins, the autocatalytic set can be used to obtain, through immunization in an animal, polyclonal sera recognizing a very large number of the constituents of the autocatalytic set.

These sera can be utilized to screen the library of stochastic genes to find those genQs expressing proteins able to combine with the antibodies present in the sera.

This set of stochastic genes expresses a large number of coded stochastic proteins which persist in the autocataly tic set. The remainder of the coded constituents of such an autocatalytic set can be isoiated by serial diminution of the Iibrary of stochastic genes, from which the subset detected by immunological methods has f i rst been subtracted.

Such autocatalytic sets of peptides and proteins, obtained as noted, may find a number of practical applications.

Claims (42)

Claims:
1. Procedure for the production of peptides or polypeptides by microbiological means, characterized by the fact that genes, which are at least partially composed of stochastic synthetic polynucleotides are produced simultaneously in a common milieu, that the genes thus obtained are introduced into host cells, that the independent clones of the transformed host cells containing these genes are simultaneously cultivated so as to clone the stochastic genes and lead to the production of proteins expressed by each of these stochastic genes, that screening and/or selection is carried out on such clones of transformed host cells in a manner to identify those clones producing peptides or polypeptides having at least one specified property, that the clones so identified are isolated, then grown in a manner so as to produce at least one peptide or polypeptide having the said property.
2. A procedure according to claim 1, characterized by the fact that these genes are produced by stochastic copolymerization of the four types of deoxyphosphonucleotides A, C, G, and T, starting from the two extremities of an expression vector which was previously linearized, then by formation of cohesive extremities in a manner to create a first strand of stochastic DNA constituted of a molecule of expression vector possessing two stochastic sequences whose 3' extremities are complementary, followed by synthesis of the second strand of the stochastic DNA.
3. A procedure according to claim 1, characterized by the fact that the genes are produced by stochastic copolymerization of double stranded oligonucleotides which do not have cohesive ends, in a manner so as to form fragments of stochastic DNA, followed by ligation of these fragments in an expression vector which was previously linearized.
4. A procedure according to claim 2 or 3, characterized by the fact that the expression vector is a plasmid.
5. A procedure according to claim 4, characterized by the fact that the expression vector is pUC8.
6. A procedure according to claim 2 or claim 3, characterized by the fact that the expression vector is a fragment of viral DNA.
7. A procedure according to claim 2 or claim 3, characterized by the fact that the expression vector is a hybrid of plasmid and viral DNA.
8. A procedure according to any one of claims 1 to 7 characterized by the fact that the host cells are prokaryotic cells.
9. A procedure according to any one of claims 1 to 7 characterized by the fact that the host cells are eukaryotic cells.
10. A procedure according to claim 8, characterized by the fact that the host cells are chosen among HB101 and C600.
11. A procedure according to claim 3, characterized by the fact that the oligonucleotides form a group of palindromic octamers.
12. A procedure according to claim 11, characterized by the fact that the group of palindromic octamers is the following group:

5' GGAATTCC 3' 5' GGTCGACC 3' 5' CAAGCTTG 3' 5' CCATATGG 3' 5' CATCGATG 3'.
13. A procedure according to claim 3, characterized by the fact that the oligonucleotides form a group of palindromic heptamers.
14. A procedure according to claim 13, characterized by the fact that the group of palindromic heptamers is the following group:

5' XTCGCGA 3' 5' XCTGCAG 3' 5' RGGTACC 3' where X = A, G, C, or T and R = A or T.
15. A procedure according to claim 1, characterized by the fact that the said property is the capacity to catalyse a given chemical reaction.
16. A procedure according to claim 1 for the production of several peptides and/or polypeptides characterized by the fact that the said property is the capacity to catalyse a sequence of reactions leading from a given group of initial chemical compounds to at least one target compound.
17. A procedure according to claim 15 for the production of an ensemble consisting of more than one peptide and/or polypeptide which is reflexively autocatalytic, characterized by the fact that the said property is the capacity to catalyse the synthesis of the ensemble itself starting from amino acids and/or oligopeptides.
18. A procedure according to claim 1, characterized by the fact that the said property is the capacity to modify selectively the chemical and/or biological properties of a given compound.
19. A procedure according to claim 18, characterized by the fact that the said property is the capacity to modify selectively the catalytic activity of a polypeptide.
20. A procedure according to claim 18, characterized by the fact that the said property is the capacity to simulate or modify at least one biological function of at least one biologically active compound.
21. A procedure according to claim 20 characterized by the fact that the said biologically active compound is chosen among the hormones, neurotransmitters, adhesion or growth factors, and specific regulators of replication and/or transcription of DNA, and/or translation of RNA.
22. A procedure according to claim 1, characterized by the fact that the said property is the capacity to bind to a given ligand.
23. A procedure according to claim 1, characterized by the fact that the said property is to have at least one epitope similar to one of the epitopes of a given antigen.
24. A procedure according to claims 18 or 23, characterized by the fact that the said property is the capacity to simulate or modify the effects of a biologically active molecule, and that screening and/or selection of the clones of transformed host cells producing at least one peptide or polypeptide having this property is carried out by preparing or obtaining antibodies against said molecule, and utilizing these antibodies obtained to identify those clones containing those peptides or polypeptides bound by the antibodies, then by growing the clones thus identified and separating and purifying the peptide or polypeptide(s) produced by these clones, and finally by submitting these peptide(s) or polypeptide(s) to an assay in vitro to verify that said peptide(s) or polypeptide(s) have in fact the capacity to simulate or modify the effects of the said molecule wherein improvement in the capacity to simulate or modify the effects of the said molecule can be obtained by modification through mutation or otherwise of the stochastic genes coding for the identified peptides or polypeptides, followed by rescreening and retesting, or derivatization of those identified peptides or polypeptides by techniques known in themselves.
25. Procedure according to claim 23, characterized by the fact that the antigen is EGF.
26. A procedure according to claim 1, characterized by the fact that clones of transformed host cells producing peptides or polypeptides having the said property are identified and isolated by affinity chromatography on antibodies corresponding to a protein expressed by a natural fragment of a DNA hybrid.
27. A procedure according to claim 26, characterized by the fact that the natural fragment of the DNA hybrid contains a gene expressing .beta. galactosidase, and that one identifies and isolates the said clones of transformed cell hosts by affinity chromatography with anti .beta.
galactosidase antibodies.
28. A procedure according to claim 1, characterized by the fact that the host cells consist in bacteria of Escherichia coli type, whose genome contains neither the natural .beta. galactosidase gene, nor the EBG gene. (Z-, EBG-E. coli), and that these transformed host cells are cultured in an X-gal medium also containing the inducer IPTG, that clones which are positive for .beta. galactosidase function are detected in the culture milieu, that thereafter the corresponding DNA is transplanted to a clone of host cells appropriate for industrial production of at least one peptide, polypeptide or protein with .beta.
galactosidase function.
29. A procedure according to claim 1, characterized by the fact that the said property is the capacity to bind to a given compound.
30. A procedure according to claim 29, characterized by the fact that the said compound is a peptide, polypeptide or protein.
31. A procedure according to claim 30, characterized by the fact that the said proteins are proteins regulating the transcription activity or replication of DNA.
32. A procedure according to claim 29, characterized by the fact that the said compound is a sequence of DNA or RNA.
33. A procedure to produce DNA characterized by the fact that, in the same milieu, genes which are at least partially composed of stochastic synthetic polynucleotide are produced, that the genes so produced are introduced into host cells in a manner to produce an ensemble of transformed host cells, that these are grown so as to produce independent clones of the host cells so produced, that screening and/or selection is carried out on this ensemble to identify those host cells which contain those stochastic sequences of DNA having at least one desired property, and that such DNA is isolated from the identified cultures of the host cells.
34. A procedure according to claim 33, characterized by the fact that the said property is the capacity to bind to a given compound.
35. A procedure according to claim 34, characterized by the fact that the said compound is a peptide, polypeptide or protein.
36. A procedure according to claim 34, characterized by the fact that the said compound is a compound regulating the transcription activity or the replication of DNA.
37. A procedure according to claim 36, characterized by the fact that the said compound is a regulatory protein controlling the transcription or replication of DNA.
38. A procedure according to claim 32, characterized by the fact that the proteins obtained have the capacity to modify the transcription activity, the replication, or the stability of DNA.
39. A procedure for the production of RNA, characterized by the fact that in the same milieu, genes which are at least partially composed of synthetic stochastic polynucleotides are produced simultaneously, that the genes thus obtained are introduced in host cells in a manner to produce an ensemble of transformed host cells, that the independent clones of transformed host cells so produced are grown simultaneously, that a screening and/or selection is carried out on this ensemble in a manner to identify those host cells which contain stochastic sequences of RNA having at least one desired property, and that the RNA is isolated from the cultures of host cells so identified.
40. A procedure according to claim 39, characterized by the fact that the said property is the capacity to bind to a given compound.
41. A procedure according to claim 39, characterized by the fact that the said property is the capacity to catalyse a given chemical reaction.
42. A procedure according to claim 39, characterized by the fact that the said property is to be a transfer RNA.
CA000617095A 1985-03-30 1986-03-20 Procedure for obtaining dna, rna, peptides, polypeptides, or proteins byrecombinant dna techniques Active CA1341595C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH137985 1985-03-30
CH1379/85-8 1985-03-30

Publications (1)

Publication Number Publication Date
CA1341595C true CA1341595C (en) 2009-04-28

Family

ID=4209046

Family Applications (2)

Application Number Title Priority Date Filing Date
CA000504653A Expired - Lifetime CA1339937C (en) 1985-03-30 1986-03-20 Procedure for obtaining dna, rna peptides, polypeptides, or proteins by recombinant dna techniques
CA000617095A Active CA1341595C (en) 1985-03-30 1986-03-20 Procedure for obtaining dna, rna, peptides, polypeptides, or proteins byrecombinant dna techniques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA000504653A Expired - Lifetime CA1339937C (en) 1985-03-30 1986-03-20 Procedure for obtaining dna, rna peptides, polypeptides, or proteins by recombinant dna techniques

Country Status (14)

Country Link
US (7) US5723323A (en)
EP (3) EP0590689B2 (en)
JP (4) JP2584613B2 (en)
CN (1) CN86102090A (en)
AU (1) AU4434585A (en)
CA (2) CA1339937C (en)
CH (1) CH0229046H1 (en)
DE (7) DE229046T1 (en)
FR (1) FR2579618B1 (en)
GB (1) GB2183661B (en)
HK (1) HK20292A (en)
IN (2) IN165561B (en)
SG (1) SG7992G (en)
WO (1) WO1986005803A1 (en)

Families Citing this family (744)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US20060008806A1 (en) * 1986-07-17 2006-01-12 University Of Washington Method for producing novel DNA sequence with biological activity
US5824469A (en) * 1986-07-17 1998-10-20 University Of Washington Method for producing novel DNA sequences with biological activity
US5266684A (en) * 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
EP0494955B1 (en) * 1989-10-05 1998-07-15 Optein, Inc. Cell-free synthesis and isolation of novel genes and polypeptides
CA2075974C (en) * 1990-02-15 2001-02-06 Dana M. Fowlkes Totally synthetic affinity reagents
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6569620B1 (en) 1990-06-11 2003-05-27 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5837834A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5756287A (en) * 1990-06-11 1998-05-26 Nexstar Pharmaceuticals, Inc. High affinity HIV integrase inhibitors
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5789163A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
EP1493825A3 (en) * 1990-06-11 2005-02-09 Gilead Sciences, Inc. Method for producing nucleic acid ligands
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US6177557B1 (en) 1990-06-11 2001-01-23 Nexstar Pharmaceuticals, Inc. High affinity ligands of basic fibroblast growth factor and thrombin
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5688935A (en) * 1990-06-11 1997-11-18 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5527894A (en) * 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US6124449A (en) * 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US5641629A (en) * 1990-06-11 1997-06-24 Nexstar Pharmacueticals Inc Spectroscopically detectable nucleic acid ligands
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US5849890A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5780228A (en) * 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US6465189B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US5731144A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5543293A (en) * 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5795721A (en) * 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US6696252B2 (en) 1990-06-11 2004-02-24 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6001988A (en) * 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5726017A (en) * 1990-06-11 1998-03-10 Nexstar Pharmaceuticals, Inc. High affinity HIV-1 gag nucleic acid ligands
US5567588A (en) * 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5763566A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5869641A (en) * 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US5972599A (en) * 1990-06-11 1999-10-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
US5864026A (en) * 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5874557A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5731424A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US5637682A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to the tachykinin substance P
US6759392B1 (en) 1990-06-11 2004-07-06 Gilead Sciences, Inc. High affinity RNA ligands of basic fibroblast growth factor
US5750342A (en) * 1990-06-11 1998-05-12 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5763177A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5587468A (en) * 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US5837456A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5853984A (en) * 1990-06-11 1998-12-29 Nexstar Pharmaceuticals, Inc. Use of nucleic acid ligands in flow cytometry
US5686592A (en) * 1990-06-11 1997-11-11 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5693502A (en) * 1990-06-11 1997-12-02 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5846713A (en) * 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US20040132067A1 (en) * 1990-06-11 2004-07-08 Somalogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US5712375A (en) * 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
DE69233697T2 (en) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Process for the development of binding microproteins
US6028186A (en) * 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US6762290B1 (en) * 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
WO1993003172A1 (en) * 1991-08-01 1993-02-18 University Research Corporation Systematic polypeptide evolution by reverse translation
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
DK1024191T3 (en) * 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
US5656467A (en) * 1992-01-09 1997-08-12 The Trustees Of The University Of Pennsylvania Methods and materials for producing gene libraries
EP1477558A1 (en) * 1992-03-16 2004-11-17 WOHLSTADTER, Jacob Nathaniel Selection methods
US5869644A (en) * 1992-04-15 1999-02-09 The Johns Hopkins University Synthesis of diverse and useful collections of oligonucleotidies
US5719273A (en) * 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5998142A (en) * 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
WO1995010296A1 (en) * 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
PT744958E (en) 1994-01-31 2003-11-28 Univ Boston BANKS OF POLYCLONE ANTIBODIES
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US20060257890A1 (en) * 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US7153948B2 (en) 1994-04-25 2006-12-26 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
JPH10506463A (en) * 1994-09-21 1998-06-23 サイトーゲン コーポレーション Antigen-binding peptide (abtide) from peptide library
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
ATE274520T1 (en) * 1995-05-03 2004-09-15 Gilead Sciences Inc SYSTEMATIC EVOULTION OF LIGANDS THROUGH EXPONENTIAL ENHANCEMENT: TISSUE-SELEX
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6207816B1 (en) 1995-06-02 2001-03-27 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to growth factors
US20090118481A1 (en) * 1995-06-07 2009-05-07 Gilead Sciences, Inc. High Affinity Nucleic Acid Ligands To Lectins
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6475806B1 (en) 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
DE69638318D1 (en) * 1995-06-07 2011-02-17 Gilead Sciences Inc Nucleic acid ligands that bind to and inhibit DNA polymerases
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US6183967B1 (en) 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US7018793B1 (en) * 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US20020028443A1 (en) * 1999-09-27 2002-03-07 Jay M. Short Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6361974B1 (en) * 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US20020164580A1 (en) * 1995-12-07 2002-11-07 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
AU725716C (en) 1996-01-23 2003-02-20 Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6838238B1 (en) 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6426335B1 (en) * 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
EP0948632A1 (en) 1996-10-31 1999-10-13 Smithkline Beecham Corporation Methods for the characterization and selection of rna target motifs that bind compounds of pharmaceutical use
US20070009930A1 (en) * 1996-12-18 2007-01-11 Maxygen, Inc. Methods and compositions for polypeptide engineering
EP1007732B1 (en) 1997-01-17 2006-07-26 Maxygen, Inc. EVOLUTION OF procaryotic WHOLE CELLS BY RECURSIVE SEQUENCE RECOMBINATION
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US8207093B2 (en) * 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
ES2373110T3 (en) 1997-01-21 2012-01-31 The General Hospital Corporation SELECTION OF PROTEINS USING ARN-PROTEIN FUSIONS.
US5871924A (en) * 1997-01-27 1999-02-16 Nexstar Pharmaceuticals, Inc. Method for the production of ligands capable of facilitating aminoacyl-RNA synthesis
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
EP1690868A1 (en) 1997-10-31 2006-08-16 Maxygen, Inc. Modification of virus tropism and host range by viral genome shuffling
AU746786B2 (en) * 1997-12-08 2002-05-02 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
US20030219803A1 (en) * 1997-12-15 2003-11-27 Somalogic, Incorporated Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6261783B1 (en) 1997-12-15 2001-07-17 Gilead Sciences, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US5989823A (en) * 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20060057573A1 (en) 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
FR2782325B1 (en) * 1998-08-12 2002-05-24 Proteus METHOD OF IDENTIFYING POLYNUCLEOTIDE SEQUENCES AND / OR CORRESPONDING PROTEINS FROM A SAMPLE OF NUCLEIC ACIDS
US7157083B2 (en) * 1998-04-17 2007-01-02 Surrogate Pharmaceutical Pathways, Llc Compositions and methods for treating retroviral infections
EP1073670A1 (en) 1998-05-01 2001-02-07 Maxygen, Inc. Optimization of pest resistance genes using dna shuffling
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
DE69941193D1 (en) 1998-08-17 2009-09-10 Bristol Myers Squibb Co IDENTIFICATION OF COMPOUND PROTEIN INTERACTIONS WITH LIBRARIES OF COUPLED PROTEIN NUCLEIC ACID MOLECULES
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
US6570003B1 (en) * 2001-01-09 2003-05-27 Lexion Genetics Incorporated Human 7TM proteins and polynucleotides encoding the same
DE60042730D1 (en) * 1999-01-05 2009-09-24 Univ Boston IMPROVED CLONING PROCESS
US20030054390A1 (en) * 1999-01-19 2003-03-20 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
WO2000042559A1 (en) * 1999-01-18 2000-07-20 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US20070065838A1 (en) * 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US20090130718A1 (en) * 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
CA2362737A1 (en) 1999-03-05 2000-09-08 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7332308B1 (en) 1999-05-21 2008-02-19 The Penn State Research Foundation Incrementally truncated nucleic acids and methods of making same
US6280943B1 (en) * 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
EP1860188B1 (en) 1999-07-07 2011-05-04 ZymoGenetics, Inc. Human cytokine receptor
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
US7005260B1 (en) 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
ATE428719T1 (en) * 1999-07-29 2009-05-15 Gilead Sciences Inc NUCLEIC ACID LIGANDS FOR HEPATOCYTIC GROWTH FACTOR/DISPERSION FACTOR (HGF/SF) AND ITS C-MET RECEPTOR
US6171795B1 (en) 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
US6864079B2 (en) 2001-04-06 2005-03-08 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6586230B1 (en) * 2000-10-27 2003-07-01 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6841377B1 (en) * 2001-06-13 2005-01-11 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6797510B1 (en) * 2001-05-24 2004-09-28 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US20080050809A1 (en) * 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
US6777545B2 (en) * 2001-04-06 2004-08-17 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6541252B1 (en) 2000-05-19 2003-04-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU784983B2 (en) * 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
WO2001053539A1 (en) 2000-01-24 2001-07-26 Phylos, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US7022479B2 (en) * 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US20020077464A1 (en) * 2000-01-26 2002-06-20 Turner C. Alexander Novel human neurexin-like proteins and polynucleotides encoding the same
US20050239061A1 (en) * 2000-03-01 2005-10-27 Marshall William S Identification and use of effectors and allosteric molecules for the alteration of gene expression
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
WO2001075178A2 (en) * 2000-04-04 2001-10-11 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US20040029113A1 (en) * 2000-04-17 2004-02-12 Ladner Robert C. Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
AU2001257091A1 (en) * 2000-04-18 2001-10-30 Gilead Sciences, Inc. Aptamer based two-site binding assay
US6479262B1 (en) 2000-05-16 2002-11-12 Hercules, Incorporated Solid phase enzymatic assembly of polynucleotides
AU2001274923A1 (en) * 2000-05-23 2001-12-03 Lexicon Genetics Incorporated Novel human thrombospondin-like proteins and polynucleotides encoding the same
WO2001094583A2 (en) * 2000-06-07 2001-12-13 Lexicon Genetics Incorporated Human transporter proteins and polynucleotides encoding the same
WO2001094417A2 (en) * 2000-06-09 2001-12-13 Lexicon Genetics Incorporated Novel human seven transmembrane proteins and polynucleotides encoding the same
US6465632B1 (en) * 2000-06-09 2002-10-15 Lexicon Genetics Incorporated Human phosphatases and polynucleotides encoding the same
EP2077279B1 (en) 2000-06-28 2012-09-05 Amgen Inc. Thymic stromal lymphopoietin receptor molecules and uses thereof
US6994963B1 (en) 2000-07-10 2006-02-07 Ambion, Inc. Methods for recombinatorial nucleic acid synthesis
WO2002006456A1 (en) * 2000-07-13 2002-01-24 Invitrogen Corporation Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
US20030017552A1 (en) * 2000-07-21 2003-01-23 Jarrell Kevin A. Modular vector systems
WO2002010183A1 (en) * 2000-07-31 2002-02-07 Menzel, Rolf Compositions and methods for directed gene assembly
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
CA2417240A1 (en) * 2000-08-07 2002-02-14 Sloan-Kettering Institute For Cancer Research Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
CA2420036A1 (en) * 2000-08-22 2002-02-28 Lexicon Genetics Incorporated Human 7tm proteins and polynucleotides encoding the same
AU2001285326A1 (en) * 2000-08-31 2002-03-13 Lexicon Genetics Incorporated Human kinase proteins and polynucleotides encoding the same
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
EP2351855A1 (en) 2000-09-26 2011-08-03 Duke University RNA aptamers and methods for identifying the same
AU2002211624A1 (en) * 2000-10-10 2002-04-22 Genencor International, Inc. Information rich libraries
AU2002224401B2 (en) 2000-10-16 2007-12-06 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
WO2002070705A2 (en) * 2000-10-27 2002-09-12 Lexicon Genetics Incorporated Human 7tm proteins and polynucleotides encoding them
AU2002232936A1 (en) * 2000-10-30 2002-05-15 Lexicon Genetics Incorporated Human 7TM proteins and polynucleotides encoding the same
WO2002042438A2 (en) * 2000-11-20 2002-05-30 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
AU2002220275A1 (en) * 2000-12-08 2002-06-18 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
CA2431007A1 (en) 2000-12-11 2002-07-18 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
AU3264202A (en) * 2000-12-12 2002-06-24 Lexicon Genetics Inc Novel human kinases and polynucleotides encoding the same
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
AU2002249854B2 (en) 2000-12-18 2007-09-20 Dyax Corp. Focused libraries of genetic packages
US6852844B1 (en) * 2000-12-20 2005-02-08 Lexicon Genetics Incorporated Human protocadherin proteins and polynucleotides encoding the same
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
WO2002059325A2 (en) * 2000-12-27 2002-08-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
JP4061043B2 (en) 2000-12-28 2008-03-12 株式会社ポストゲノム研究所 Method for producing peptide etc. by in vitro transcription / translation system
WO2002059287A2 (en) * 2001-01-23 2002-08-01 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
US7582423B2 (en) * 2001-02-02 2009-09-01 Novici Biotech Llc Population of polynucleotide sequence variants
US20040142433A1 (en) * 2001-02-02 2004-07-22 Padgett Hal S. Polynucleotide sequence variants
US7838219B2 (en) * 2001-02-02 2010-11-23 Novici Biotech Llc Method of increasing complementarity in a heteroduplex
JP4689940B2 (en) * 2001-02-02 2011-06-01 ノビシ バイオテック,リミティド ライアビリティ カンパニー Method for increasing heteroduplex complementarity
WO2002065125A1 (en) * 2001-02-13 2002-08-22 Invitrogen Corporation Methods and compositions for isolation of biological macromolecules
JP2004530117A (en) * 2001-02-22 2004-09-30 プラエシス ファーマシューティカルズ インコーポレーテッド Methods for identifying peptides that modulate biological processes
US6875845B2 (en) 2001-03-02 2005-04-05 Zymogenetics, Inc. Mouse cytokine receptor
US7678554B2 (en) 2001-03-19 2010-03-16 President And Fellows Of Harvard College Nucleic acid shuffling
US7807408B2 (en) * 2001-03-19 2010-10-05 President & Fellows Of Harvard College Directed evolution of proteins
WO2002074932A2 (en) 2001-03-20 2002-09-26 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
US6644173B2 (en) * 2001-04-11 2003-11-11 Keuring, Incorporated Beverage filter cartridge holder
EP1383887A4 (en) * 2001-05-03 2004-07-07 Rensselaer Polytech Inst Novel methods of directed evolution
CA2446967A1 (en) * 2001-05-09 2002-11-14 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
US20020193585A1 (en) * 2001-05-25 2002-12-19 Walke D. Wade Novel human transporter proteins and polynucleotides encoding the same
US7300922B2 (en) * 2001-05-25 2007-11-27 Duke University Modulators of pharmacological agents
EP1461425B1 (en) 2001-05-29 2008-02-13 Lexicon Pharmaceuticals, Inc. Novel human hydroxylases and polynucleotides encoding the same
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20030148380A1 (en) * 2001-06-05 2003-08-07 Belcher Angela M. Molecular recognition of materials
US20050164515A9 (en) * 2001-06-05 2005-07-28 Belcher Angela M. Biological control of nanoparticle nucleation, shape and crystal phase
ATE522623T1 (en) 2001-06-20 2011-09-15 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG TUMORS
DE10131441A1 (en) * 2001-06-29 2003-01-30 Henkel Kgaa A new group of alpha amylases and a method for identifying and obtaining new alpha amylases
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
JP2004533840A (en) * 2001-07-06 2004-11-11 ジェネンテック・インコーポレーテッド PDZ domain ligand by phage display
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
WO2003012126A2 (en) * 2001-08-03 2003-02-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
DE10138753B4 (en) * 2001-08-07 2017-07-20 Henkel Ag & Co. Kgaa Detergents and cleaners with hybrid alpha-amylases
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
EP2153843B1 (en) 2001-09-18 2012-08-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE60232672D1 (en) 2001-10-01 2009-07-30 Dyax Corp MULTILACKED EUKARYONTIC DISPLAY VECTORS AND THEIR USES
US20030073104A1 (en) * 2001-10-02 2003-04-17 Belcher Angela M. Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
WO2005049075A2 (en) 2003-11-17 2005-06-02 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
EP1840211A1 (en) 2001-10-31 2007-10-03 Danisco A/S Pyranosone dehydratase from phanerochaete chrysosporium
WO2004039826A1 (en) 2001-11-14 2004-05-13 Centocor, Inc. Anti-il-6 antibodies, compositions, methods and uses
DE60232688D1 (en) * 2001-11-20 2009-07-30 Univ Duke BOUNDARY-BIOMATERIALS
WO2003050914A1 (en) * 2001-12-05 2003-06-19 E-Tenna Corporation Capacitively-loaded bent-wire monopole on an artificial magnetic conductor
WO2003051314A2 (en) 2001-12-18 2003-06-26 Medallion Biomedical, Llc Antibiotic compounds
WO2003057921A1 (en) * 2001-12-26 2003-07-17 Sloan Kettering Institute For Cancer Research Dna immunization with libraries of minigenes encoding degenerate variants of major histocompatibility class i restricted epitopes
JP2005525095A (en) 2002-01-02 2005-08-25 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
WO2003064612A2 (en) * 2002-01-28 2003-08-07 Sloan-Kettering Institute For Cancer Research Identification of mutant antigens with enhanced immunogenicity
US20030157495A1 (en) * 2002-02-01 2003-08-21 Padgett Hal S. Nucleic acid molecules encoding CEL I endonuclease and methods of use thereof
US7078211B2 (en) * 2002-02-01 2006-07-18 Large Scale Biology Corporation Nucleic acid molecules encoding endonucleases and methods of use thereof
US20040025194A1 (en) * 2002-02-22 2004-02-05 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
WO2003072054A2 (en) * 2002-02-25 2003-09-04 Cabot Corporation Custom ligand design for biomolecular filtration and purification for bioseperation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP2011886A3 (en) 2002-04-16 2009-02-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
EP1497418B1 (en) 2002-04-19 2012-10-17 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
DK1504098T4 (en) * 2002-05-17 2011-05-23 Alligator Bioscience Ab Process for molecular evolution in vitro of protein function
JP4753578B2 (en) * 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド Synthetic antibody phage library
DE60319259T2 (en) * 2002-06-14 2009-03-05 Dyax Corp., Cambridge Recombination of nucleic acid library members
CA2487809A1 (en) * 2002-06-18 2003-12-24 Archemix Corp. Aptamer-toxin molecules and methods for using same
EP1543158B1 (en) 2002-07-25 2011-07-13 Archemix Corp. Regulated aptamer therapeutics
CA2494798A1 (en) 2002-08-06 2005-01-13 Verdia, Inc. Ap1 amine oxidase variants
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
ATE466085T1 (en) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US20050064508A1 (en) * 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
EP2042517B1 (en) 2002-09-27 2012-11-14 Xencor, Inc. Optimized FC variants and methods for their generation
JP3447009B1 (en) * 2002-10-29 2003-09-16 實 平垣 Construct structure and method for producing the same
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
WO2004047742A2 (en) * 2002-11-21 2004-06-10 Archemix Corporation Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2506748A1 (en) * 2002-12-03 2004-06-17 Archemix Corporation Method for in vitro selection of 2'-substituted nucleic acids
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
AU2003303459A1 (en) * 2002-12-26 2004-07-22 Applied Research Systems Ars Holding N.V. Spliced variants of lgr6
WO2004065416A2 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
ES2713024T3 (en) 2003-03-06 2019-05-17 Basf Enzymes Llc Amylases, nucleic acids that encode them and methods for their manufacture and use
EP1601332A4 (en) 2003-03-07 2012-05-02 Verenium Corp Hydrolases, nucleic acids encoding them and mehods for making and using them
ES2545639T3 (en) 2003-04-04 2015-09-14 Basf Enzymes Llc Pectate liases, nucleic acids that encode them and methods for their preparation and use
US20050250106A1 (en) * 2003-04-24 2005-11-10 David Epstein Gene knock-down by intracellular expression of aptamers
US7964714B2 (en) * 2003-05-12 2011-06-21 Potomac Pharmaceuticals Inc. Gene expression suppression agents
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US7960148B2 (en) 2003-07-02 2011-06-14 Verenium Corporation Glucanases, nucleic acids encoding them and methods for making and using them
SI1641822T1 (en) 2003-07-08 2013-08-30 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
WO2005012487A2 (en) * 2003-08-01 2005-02-10 Invitrogen Corporation Compositions and methods for preparing short rna molecules and other nucleic acids
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
CA2535526C (en) 2003-08-11 2015-09-29 Diversa Corporation Laccases, nucleic acids encoding them and methods for making and using them
AU2004280333A1 (en) * 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
JP2005065575A (en) * 2003-08-22 2005-03-17 Japan Science & Technology Agency Preparation of protein molecular-diversified population by frame shuffling
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US20050112585A1 (en) * 2003-11-21 2005-05-26 Dominic Zichi Method for adjusting the quantification range of individual analytes in a multiplexed assay
AU2004297616B2 (en) * 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP1701672A4 (en) * 2003-12-19 2011-04-27 Osteotech Inc Tissue-derived mesh for orthopedic regeneration
WO2005079363A2 (en) 2004-02-12 2005-09-01 Archemix Corporation Aptamer therapeutics useful in the treatment of complement-related disorders
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
JP2007527246A (en) * 2004-03-05 2007-09-27 アーケミックス コーポレイション Aptamers against the human IL-12 cytokine family and their use as therapeutics for autoimmune diseases
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US7569223B2 (en) * 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
PL1745062T3 (en) * 2004-04-22 2014-10-31 Regado Biosciences Inc Improved modulators of coagulation factors
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
WO2005106012A2 (en) 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
US20060292554A1 (en) * 2004-05-18 2006-12-28 Genentech, Inc. Major coat protein variants for C-terminal and bi-terminal display
EA013993B1 (en) 2004-06-16 2010-08-30 Верениум Корпорейшн Compositions and methods for enzymatic de-colorization of chlorophyll
BRPI0514984A (en) 2004-09-07 2008-07-01 Archemix Corp aptamers for von willebrand factor and their use as therapeutics for thrombotic disease
AU2005282380A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
GB0422052D0 (en) 2004-10-04 2004-11-03 Dansico As Enzymes
GB0423139D0 (en) 2004-10-18 2004-11-17 Danisco Enzymes
CN102746404B (en) 2004-11-12 2016-01-20 赞科股份有限公司 To FcRn in conjunction with reformed Fc variant
ES2323651T3 (en) 2005-01-05 2009-07-22 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. IMMUNOGLOBULIN SYNTHETIC DOMAINS WITH UNION PROPERTIES DEVELOPED BY ENGINEERING IN MOLECULA REGIONS DIFFERENT FROM THE REGIONS THAT DETERMINE COMPLEMENTARITY.
PA8660701A1 (en) 2005-02-04 2006-09-22 Pfizer Prod Inc SMALL AGONISTS AND THEIR USES
JP2008532931A (en) 2005-02-08 2008-08-21 ザイモジェネティクス, インコーポレイテッド Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and uses in inflammation
CN101175769A (en) 2005-03-10 2008-05-07 健泰科生物技术公司 Methods and compositions for modulating vascular integrity
WO2006099207A2 (en) 2005-03-10 2006-09-21 Diversa Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
CA2861310A1 (en) 2005-03-15 2006-09-28 Bp Corporation North America Inc. Cellulases, nucleic acids encoding them and methods for making and using them
PA8672101A1 (en) 2005-04-29 2006-12-07 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
ATE515512T1 (en) 2005-05-12 2011-07-15 Zymogenetics Inc COMPOSITIONS AND METHODS FOR MODULATING IMMUNE REACTIONS
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
US8389469B2 (en) * 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US7491391B2 (en) 2005-06-30 2009-02-17 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
BRPI0611714A2 (en) * 2005-06-30 2009-01-13 Abbott Lab il-12 / p40 binding proteins
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP2500354A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (en) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
DE602006018746D1 (en) 2005-08-24 2011-01-20 Univ Rockefeller PLY-GBS MUTANT LYSINE
US7713689B2 (en) 2005-09-15 2010-05-11 Duke University Non-fouling polymeric surface modification and signal amplification method for biomolecular detection
JP2009510002A (en) * 2005-09-30 2009-03-12 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Binding domains of proteins of the repulsion-inducing molecule (RGM) protein family, and functional fragments thereof, and uses thereof
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
PL1954718T3 (en) * 2005-11-30 2015-04-30 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
WO2007064972A2 (en) * 2005-11-30 2007-06-07 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2635692C (en) 2005-12-29 2013-06-18 Centocor, Inc. Human anti-il-23 antibodies, compositions, methods and uses
EP1987142A4 (en) 2006-02-02 2009-07-15 Verenium Corp Esterases and related nucleic acids and methods
WO2007092313A2 (en) * 2006-02-03 2007-08-16 Indiana University Research And Technology Corporation Construction of open reading frame libraries and protein structures
MY160772A (en) 2006-02-10 2017-03-15 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
BRPI0707784B1 (en) 2006-02-14 2018-05-22 Verenium Corporation ISOLATED, SYNTHETIC OR RECOMBINANT NUCLEIC ACID, EXPRESSION CASSETTE, CLONING VECTOR OR VEHICLE, TRANSFORMED ISOLATED HOST CELL, AND METHOD FOR PRODUCTION OF A RECOMBINANT POLYPEPTIDE
US8043837B2 (en) 2006-03-07 2011-10-25 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
ATE548450T1 (en) 2006-03-07 2012-03-15 Verenium Corp ALDOLASES, NUCLEIC ACIDS FOR ENCODING THEM AND METHODS FOR THEIR PRODUCTION AND USE
PT2596807E (en) * 2006-03-08 2016-03-18 Archemix Llc Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
TW200812616A (en) * 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
AT503861B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
KR101193722B1 (en) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 Exendin fusion proteins
CN101528766A (en) 2006-08-04 2009-09-09 维莱尼姆公司 Glucanases, nucleic acids encoding them and methods for making and using them
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp Organ-specific proteins and methods of their use
KR101625961B1 (en) 2006-09-08 2016-05-31 애브비 바하마스 리미티드 Interleukin-13 binding proteins
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
CA2663001A1 (en) 2006-09-21 2008-03-27 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
EP2617729B1 (en) 2006-09-21 2016-03-16 BASF Enzymes LLC Phytases, nucleic acids encoding them and methods for making and using them
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
DK3101128T3 (en) 2006-12-21 2019-07-08 Basf Enzymes Llc AMYLASES AND GLUCOAMYLASES, NUCLEAR ACIDS CODING FOR THESE, AND METHODS OF MANUFACTURE AND USE THEREOF
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
AU2008205457A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
WO2008095033A2 (en) 2007-01-30 2008-08-07 Verenium Corporation Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
US8143046B2 (en) 2007-02-07 2012-03-27 Danisco Us Inc., Genencor Division Variant Buttiauxella sp. phytases having altered properties
JP5675109B2 (en) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド Library generation method and use thereof
KR101508397B1 (en) 2007-02-22 2015-04-08 제넨테크, 인크. Methods for detecting inflammatory bowel disease
EP2124952A2 (en) * 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
PE20090329A1 (en) * 2007-05-30 2009-03-27 Abbott Lab HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
WO2009000006A1 (en) 2007-06-26 2008-12-31 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Display of binding agents
EP2172566B2 (en) 2007-07-17 2022-05-18 Somalogic, Inc. Method for generating aptamers with improved off-rates
EP2033971A1 (en) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application
JP5933894B2 (en) 2007-09-14 2016-06-15 アディマブ, エルエルシー Rationally designed synthetic antibody libraries and their use
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5637561B2 (en) 2007-09-28 2014-12-10 ポートラ ファーマシューティカルズ, インコーポレイテッド Antidote to factor Xa inhibitor and method of use thereof
US8486680B2 (en) 2007-10-03 2013-07-16 Bp Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
WO2009055005A2 (en) 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding
WO2009055656A2 (en) 2007-10-26 2009-04-30 Centocor, Inc. Vectors, host cells, and methods of production and uses
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
WO2009088928A2 (en) * 2007-12-31 2009-07-16 Xoma Technology Ltd. Libraries, arrays and their uses for targeted affinity enhancement
CN104651381A (en) 2008-01-03 2015-05-27 巴斯夫酶有限责任公司 Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
EP2706122A3 (en) 2008-01-03 2014-06-18 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
US7682809B2 (en) 2008-01-11 2010-03-23 Agilent Technologies, Inc. Direct ATP release sequencing
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
WO2009132287A2 (en) * 2008-04-24 2009-10-29 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
KR20110014607A (en) 2008-04-29 2011-02-11 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009133461A1 (en) 2008-04-30 2009-11-05 Danisco A/S Composition
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CA2723219A1 (en) 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
EP3002299A1 (en) * 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
MX2010014358A (en) 2008-06-20 2011-07-04 Wyeth Llc Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains.
CA2728473A1 (en) * 2008-06-20 2009-12-23 National University Corporation Okayama University Antibody against oxidized ldl/.beta.2gpi complex and use of the same
CA2729949A1 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
EP2810654A1 (en) 2008-07-08 2014-12-10 AbbVie Inc. Prostaglandin E2 binding proteins and uses thereof
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
EP2323680A4 (en) * 2008-07-25 2013-05-01 Viral Genetics Inc Proteins for use in diagnosing and treating infection and disease
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
US9182406B2 (en) * 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
EA026110B1 (en) 2008-08-14 2017-03-31 Сефалон Острэйлиа Пти Лтд. Anti-il-12/il-23 antibodies
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
WO2010047515A2 (en) 2008-10-20 2010-04-29 광주과학기술원 Bipodal peptide binder
NZ593314A (en) * 2008-12-04 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
RU2011135768A (en) * 2009-01-29 2013-03-10 Эбботт Лэборетриз PROTEINS BINDING IL-1
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
PE20121094A1 (en) * 2009-03-05 2012-09-13 Abbvie Inc IL-17 BINDING PROTEINS
EP3604510A1 (en) 2009-03-30 2020-02-05 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
GB0908770D0 (en) 2009-04-24 2009-07-01 Danisco Method
BRPI1011160A8 (en) 2009-05-21 2018-01-02 Verenium Corp PHYTASES, PROTEIN PREPARATION INCLUDING THEM, AND THEIR USES
ES2605801T3 (en) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor Xa inhibitors for use in the prevention of bleeding
UY32808A (en) * 2009-07-29 2011-02-28 Abbott Lab IMMUNOGLOBULINS AS A DUAL VARIABLE DOMAIN AND USES OF THE SAME
MX2012002605A (en) 2009-08-29 2012-04-02 Abbott Lab Therapeutic dll4 binding proteins.
IN2012DN02737A (en) 2009-09-01 2015-09-11 Abbott Lab
EP2478136A4 (en) * 2009-09-14 2013-09-25 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA2775959A1 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UA109884C2 (en) 2009-10-16 2015-10-26 A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
UA111708C2 (en) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. METHOD OF OIL REFINING
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
UY32979A (en) * 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US8420083B2 (en) * 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
MX2012006072A (en) 2009-11-30 2012-07-23 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ).
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
SG183333A1 (en) 2010-02-18 2012-09-27 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
BR112012020373A8 (en) 2010-02-23 2018-01-02 Genentech Inc isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent
TWI672318B (en) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 Folate receptor 1 antibodies and immunoconjugates and uses thereof
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
WO2011109642A1 (en) 2010-03-03 2011-09-09 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
CN103097416B (en) 2010-03-30 2015-09-09 詹森生物科技公司 Humanization IL-25 antibody
WO2011130289A1 (en) 2010-04-12 2011-10-20 Somalogic, Inc. 5-position modified pyrimidines and their use
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
CN102958941A (en) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 Compositions and methods for the diagnosis and treatment of tumor
WO2011143562A2 (en) 2010-05-14 2011-11-17 Abbott Laboratories Il-1 binding proteins
GB201011513D0 (en) 2010-07-08 2010-08-25 Danisco Method
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US9354228B2 (en) 2010-07-16 2016-05-31 Adimab, Llc Antibody libraries
SG188190A1 (en) 2010-08-03 2013-04-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP6147665B2 (en) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド Amyloid beta-binding protein
EP3333188B1 (en) 2010-08-19 2022-02-09 Zoetis Belgium S.A. Anti-ngf antibodies and their use
CN103260639A (en) 2010-08-26 2013-08-21 Abbvie公司 Dual variable domain immunoglobulins and uses thereof
BR112013008347A2 (en) 2010-10-06 2016-06-14 Bp Corp North America Inc cbh variant polypeptides i
MY163368A (en) 2010-12-21 2017-09-15 Abbvie Inc Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
MX344595B (en) 2010-12-31 2016-12-20 Bioatla Llc Express humanization of antibodies.
WO2012129347A1 (en) 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
EP3252155A1 (en) 2011-04-21 2017-12-06 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
EP3574919A1 (en) 2011-07-13 2019-12-04 AbbVie Inc. Methods and compositions for treating asthma using anti-il-13 antibodies
WO2013016449A2 (en) 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
CN103930781A (en) 2011-09-15 2014-07-16 霍夫曼-拉罗奇有限公司 Methods of promoting differentiation
AU2012318609B2 (en) 2011-10-05 2018-02-08 The Rockefeller University Dimeric bacteriophage lysins
RU2014119426A (en) 2011-10-15 2015-11-20 Дженентек, Инк. WAYS OF APPLICATION OF SCD1 ANTAGONISTS
SG11201401791WA (en) 2011-10-24 2014-08-28 Abbvie Inc Immunobinders directed against sclerostin
DK2797957T3 (en) 2011-11-23 2019-09-23 Medimmune Llc BINDING MOLECULES SPECIFIC TO HER3 AND APPLICATIONS THEREOF
JP6336397B2 (en) 2011-12-14 2018-06-06 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Compositions and methods for diagnosing and treating iron-related disorders
EP3800200A1 (en) 2011-12-14 2021-04-07 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
CN104168920A (en) 2012-01-18 2014-11-26 霍夫曼-拉罗奇有限公司 Methods of using FGF19 modulators
AU2013209492B2 (en) 2012-01-20 2018-02-08 Genzyme Corporation Anti-CXCR3 antibodies
MX352772B (en) 2012-01-27 2017-12-07 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration.
JP6545959B2 (en) 2012-02-11 2019-07-17 ジェネンテック, インコーポレイテッド R-Spondin rearrangement and method of using the same
NZ630020A (en) 2012-03-08 2016-08-26 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
CN104394880B (en) 2012-03-16 2020-08-28 大学保健网络 Methods and compositions for modulating TOSO activity
RU2014141018A (en) 2012-03-16 2016-05-10 Ф. Хоффманн-Ля Рош Аг METHODS OF TREATING MELANOMA WITH CANCER INHIBITORS
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
KR20140142293A (en) 2012-03-16 2014-12-11 제넨테크, 인크. Engineered conformationally-stabilized proteins
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP2841951B1 (en) 2012-04-25 2019-12-11 Biodesy, Inc. Methods for detecting allosteric modulators of proteins
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
WO2013174003A1 (en) 2012-05-24 2013-11-28 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
CN104755498B (en) 2012-08-31 2019-06-18 伊缪诺金公司 For detecting the diagnostic assay and kit of folacin receptor 1
BR112015009961B1 (en) 2012-11-01 2020-10-20 Abbvie Inc. binding protein capable of binding to dll4 and vegf, as well as a composition comprising it as a composition comprising it
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
JP2016509045A (en) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト How to treat cancer and prevent drug resistance
CA2902263A1 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
GB201308828D0 (en) 2013-03-12 2013-07-03 Verenium Corp Phytase
CA2906417C (en) 2013-03-14 2022-06-21 Robert Ziemann Hcv core lipid binding domain monoclonal antibodies
US9194873B2 (en) 2013-03-14 2015-11-24 Abbott Laboratories HCV antigen-antibody combination assay and methods and compositions for use therein
US9790478B2 (en) 2013-03-14 2017-10-17 Abbott Laboratories HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
EP2968565A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
GB201308843D0 (en) 2013-03-14 2013-07-03 Verenium Corp Phytase formulation
CN105339001A (en) 2013-03-15 2016-02-17 基因泰克公司 Methods of treating cancer and preventing cancer drug resistance
EP2972373B1 (en) 2013-03-15 2019-10-09 F.Hoffmann-La Roche Ag Biomarkers and methods of treating pd-1 and pd-l1 related conditions
CN105324396A (en) 2013-03-15 2016-02-10 艾伯维公司 Dual specific binding proteins directed against il-1 beta and il-17
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
CN105473605A (en) 2013-03-15 2016-04-06 先锋国际良种公司 Phi-4 polypeptides and methods for their use
CA2914566A1 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
CN105408492A (en) 2013-07-25 2016-03-16 巴斯夫酶有限责任公司 Phytase
WO2015023846A2 (en) 2013-08-16 2015-02-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
KR20160055253A (en) 2013-09-12 2016-05-17 할로자임, 아이엔씨 Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
EA031651B1 (en) 2013-09-13 2019-02-28 Пайонир Хай-Бред Интернэшнл, Инк. Insecticidal proteins and methods for their use
KR102344991B1 (en) 2013-12-24 2021-12-28 잔센파마슈티카엔.브이. Anti-vista antibodies and fragments
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
US10480007B2 (en) 2014-02-07 2019-11-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants
ES2806473T3 (en) 2014-02-07 2021-02-17 Pioneer Hi Bred Int Insecticidal proteins and methods for their use
CA2941693A1 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
MA50678A (en) 2014-04-08 2020-08-05 Boston Pharmaceuticals Inc IL-21 SPECIFIC BINDING MOLECULES AND THEIR USES
US10160812B2 (en) 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
MA51519A (en) 2014-05-05 2020-11-11 Regeneron Pharma HUMANIZED C5 AND C3 ANIMALS
RU2016144405A (en) 2014-05-23 2018-06-26 Дженентек, Инк. MiT BIOMARKERS AND WAYS OF THEIR APPLICATION
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2015196070A1 (en) 2014-06-20 2015-12-23 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
RU2733898C2 (en) 2014-10-16 2020-10-09 Пайонир Хай-Бред Интернэшнл, Инк. Insecticidal proteins and methods of using them
BR112017008406A2 (en) 2014-10-24 2018-02-27 Dupont Nutrition Biosciences Aps use of proline tolerant tripeptidyl peptidases in food additive compositions
BR112017007949A2 (en) 2014-10-24 2018-01-23 Danisco Us Inc method for alcohol production by the use of a tripeptidyl peptidase
HUE054339T2 (en) 2014-11-10 2021-08-30 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
CA2977026A1 (en) 2015-03-11 2016-09-15 E.I. Du Pont De Nemours And Company Insecticidal combinations of pip-72 and methods of use
WO2016172485A2 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
CN116333064A (en) 2015-05-19 2023-06-27 先锋国际良种公司 Insecticidal proteins and methods of use thereof
AU2016270640B2 (en) 2015-05-29 2022-03-10 Abbvie Inc. Anti-CD40 antibodies and uses thereof
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2016210395A1 (en) 2015-06-26 2016-12-29 Dupont Nutrition Biosciences Aps Aminopeptidases for protein hydrlyzates
HUE053619T2 (en) 2015-06-29 2021-07-28 Immunogen Inc Anti-cd123 antibodies and conjugates and derivatives thereof
WO2017011275A1 (en) 2015-07-10 2017-01-19 Nersissian Aram M Factor viii protein compositions and methods of treating hemophilia a
CA2993009A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
RU2762832C2 (en) 2015-08-06 2021-12-23 Пайонир Хай-Бред Интернэшнл, Инк. Insecticide proteins of plant origin and their application methods
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
EP3374398B1 (en) 2015-11-10 2020-03-18 MedImmune, LLC Binding molecules specific for asct2 and uses thereof
WO2017105987A1 (en) 2015-12-18 2017-06-22 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
EP3405478A4 (en) 2015-12-23 2019-10-30 Moonshot Pharma LLC Methods for inducing an immune response by inhibition of nonsense mediated decay
TWI756204B (en) 2016-02-12 2022-03-01 比利時商楊森製藥公司 Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017147060A1 (en) 2016-02-25 2017-08-31 Dupont Nutrition Biosciences Aps Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase
JP6987072B2 (en) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド Activin type 2 receptor binding protein and its use
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EA202190162A3 (en) 2016-04-27 2021-11-30 Эббви Инк. METHODS FOR TREATING DISEASES IN WHICH IL-13 ACTIVITY HAS A NEGATIVE EFFECT, USING ANTIBODIES AGAINST IL-13
CN109068660B (en) 2016-05-04 2023-05-02 先锋国际良种公司 Insecticidal proteins and methods of use thereof
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
JP2019521973A (en) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド Anti-BH7-H3 antibody and antibody drug conjugate
JP6751165B2 (en) 2016-06-08 2020-09-02 アッヴィ・インコーポレイテッド Anti-B7-H3 antibody and antibody drug conjugate
BR112018075653A2 (en) 2016-06-08 2019-08-27 Abbvie Inc anti-b7-h3 antibodies and drug antibody conjugates
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP3472186A1 (en) 2016-06-17 2019-04-24 National Hellenic Research Foundation Systems for recombinant protein production
WO2018005411A1 (en) 2016-07-01 2018-01-04 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
JP2019534858A (en) 2016-09-09 2019-12-05 ジェネンテック, インコーポレイテッド Selective peptide inhibitor of FRIZZLED
MX2019003703A (en) 2016-09-30 2020-08-13 Janssen Biotech Inc Safe and effective method of treating psoriasis with anti-il23 specific antibody.
WO2018067468A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing uch-l1 status in patient samples
EP3535285B1 (en) 2016-11-01 2022-04-06 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
AU2017362222A1 (en) 2016-11-16 2019-05-30 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL-23 specific antibody
KR20190080949A (en) 2016-11-23 2019-07-08 바이오버라티브 테라퓨틱스 인크. A bispecific antibody that binds to coagulation factor IX and coagulation factor X
JP7274417B2 (en) 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド 4-1BB binding protein and uses thereof
US11174295B2 (en) 2016-12-14 2021-11-16 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3046226A1 (en) 2016-12-22 2018-06-28 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
TW201825515A (en) 2017-01-04 2018-07-16 美商伊繆諾金公司 Met antibodies and immunoconjugates and uses thereof
CA3049114A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Antibody fragments for the treatment of biofilm-related disorders
AU2018206552A1 (en) 2017-01-04 2019-07-18 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
CN110709419B (en) 2017-01-06 2023-11-28 博奥信生物技术(南京)有限公司 ERBB2 antibodies and uses thereof
MA47362A (en) 2017-01-30 2019-12-04 Janssen Biotech Inc ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE PSORIASIC RHEUMATISM
WO2018147915A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
CA3052794A1 (en) 2017-02-08 2018-08-16 Pioneer Hi-Bred International, Inc. Insecticidal combinations of plant derived insecticidal proteins and methods for their use
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018157027A1 (en) 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
CA3053409A1 (en) 2017-04-15 2018-10-18 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
TW201841656A (en) 2017-04-21 2018-12-01 美商建南德克公司 Use of klk5 antagonists for treatment of a disease
US11236151B2 (en) 2017-04-25 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
CN110603449A (en) 2017-04-28 2019-12-20 雅培实验室 Method for determining traumatic brain injury using early biomarkers from at least two samples of the same human subject for aiding hyperacute diagnosis
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
WO2018208882A1 (en) 2017-05-11 2018-11-15 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
AU2018272054A1 (en) 2017-05-25 2019-09-26 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
JP7269182B2 (en) 2017-05-30 2023-05-08 アボット・ラボラトリーズ Methods to Help Diagnose and Assess Mild Traumatic Brain Injury in Human Subjects Using Cardiac Troponin I and Early Biomarkers
US11654135B2 (en) 2017-06-22 2023-05-23 Moonshot Pharma Llc Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
JP2020526745A (en) 2017-07-03 2020-08-31 アボット・ラボラトリーズAbbott Laboratories An improved method for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
JP6889328B2 (en) 2017-07-31 2021-06-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Humanization method based on three-dimensional structure
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
JP2020536115A (en) 2017-10-04 2020-12-10 オプコ ファーマシューティカルズ、エルエルシー Articles and methods for personalized cancer therapy
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
WO2019094595A2 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
US11016105B2 (en) 2017-12-09 2021-05-25 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
EP3721233A2 (en) 2017-12-09 2020-10-14 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
EP3728321A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Use of pilra binding agents for treatment of a disease
WO2019133717A1 (en) 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
WO2019160976A1 (en) 2018-02-14 2019-08-22 Viela Bio, Inc. Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US10982002B2 (en) 2018-03-12 2021-04-20 Zoetis Services Llc Anti-NGF antibodies and methods thereof
WO2019213619A1 (en) 2018-05-04 2019-11-07 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
WO2019222226A2 (en) 2018-05-17 2019-11-21 Bp Corporation North America Inc. Production of 2-keto-3-deoxy-d-gluconic acid in filamentous fungi
TW202016144A (en) 2018-06-21 2020-05-01 日商第一三共股份有限公司 Compositions including cd3 antigen binding fragments and uses thereof
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3824295A4 (en) 2018-07-18 2022-04-27 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
AU2019334671A1 (en) 2018-09-07 2021-03-25 Basf Plant Science Company Gmbh Improved method for the production of high levels of PUFA in plants
CA3110664A1 (en) 2018-09-07 2020-03-12 Basf Plant Science Company Gmbh Improved method for the production of high levels of pufa in plants
CA3110651A1 (en) 2018-09-07 2020-03-12 Basf Plant Science Company Gmbh Improved method for the production of high levels of pufa in plants
KR20230148273A (en) 2018-09-24 2023-10-24 얀센 바이오테크 인코포레이티드 Safe and effective method of treating ulcerative colitis with anti-IL12/IL23 antibody
JP2022512580A (en) 2018-10-05 2022-02-07 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Compositions and Methods for Enzymatic Destruction of Bacterial Biofilms
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
JP2022507836A (en) 2018-11-20 2022-01-18 タケダ ワクチン,インコーポレイテッド New anti-Zika virus antibody and its use
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
WO2020132557A1 (en) 2018-12-21 2020-06-25 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
AU2020208828A1 (en) 2019-01-15 2021-08-05 Janssen Biotech, Inc. Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
EP3914618A1 (en) 2019-01-23 2021-12-01 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
EP3938384A4 (en) 2019-03-14 2022-12-28 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
US20220144934A1 (en) 2019-03-14 2022-05-12 Janssen Biotech, Inc. Methods for Producing Anti-TNF Antibody Compositions
US20220153830A1 (en) 2019-03-14 2022-05-19 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
EA202192508A1 (en) 2019-03-14 2022-03-29 Янссен Байотек, Инк. METHODS FOR OBTAINING COMPOSITIONS OF ANTIBODIES TO TNF
WO2020188466A1 (en) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
JP7397884B2 (en) 2019-05-09 2023-12-13 ジェネンテック, インコーポレイテッド How to make antibodies
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CA3142580A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
CN113939531A (en) 2019-06-03 2022-01-14 詹森生物科技公司 anti-TNF antibody compositions and methods for treating psoriatic arthritis
EP3997120A4 (en) 2019-07-08 2023-11-22 Research Institute at Nationwide Children's Hospital Antibody compositions for disrupting biofilms
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
CA3161024A1 (en) 2019-12-19 2021-06-24 Quidel Corporation Monoclonal antibody fusions
EP4077658A1 (en) 2019-12-20 2022-10-26 Basf Se Decreasing toxicity of terpenes and increasing the production potential in micro-organisms
US20230061973A1 (en) 2020-02-05 2023-03-02 Larimar Therapeutics, Inc. Tat peptide binding proteins and uses thereof
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
EP4136459A1 (en) 2020-04-13 2023-02-22 Abbott Laboratories Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US20230235310A1 (en) 2020-06-04 2023-07-27 Isobionics B.V. Synthetic santalene synthases
CN115867564A (en) 2020-07-14 2023-03-28 先锋国际良种公司 Insecticidal proteins and methods of use thereof
EP4193151A1 (en) 2020-08-04 2023-06-14 Abbott Rapid Diagnostics International Unlimited Company Assays for detecting sars-cov-2
KR20230042301A (en) 2020-08-04 2023-03-28 애벗트 라보라토리이즈 Improved methods and kits for detecting SARS-COV-2 proteins in samples
KR20230084497A (en) 2020-09-11 2023-06-13 메디뮨 리미티드 Therapeutic B7-H4 binding molecules
JP2023542301A (en) 2020-09-12 2023-10-06 メディミューン リミテッド Scoring method for anti-B7H4 antibody drug conjugate therapy
CA3198161A1 (en) 2020-12-01 2022-06-09 Beth MCQUISTON Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4015626A1 (en) 2020-12-18 2022-06-22 Isobionics B.V. Enzymes and methods for fermentative production of monoterpene esters
EP4271998A1 (en) 2020-12-30 2023-11-08 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
CA3204731A1 (en) 2021-01-13 2022-07-21 John T. POIRIER Anti-dll3 antibody-drug conjugate
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
UY39610A (en) 2021-01-20 2022-08-31 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
KR20230156764A (en) 2021-03-12 2023-11-14 얀센 바이오테크 인코포레이티드 Method for treating psoriatic arthritis patients with inadequate response to TNF therapy by anti-IL23 specific antibody
AU2022233792A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
CA3208011A1 (en) 2021-03-17 2022-09-22 Sarah Harris Methods of treating atopic dermatitis with anti il-13 antibodies
WO2022195028A2 (en) 2021-03-18 2022-09-22 Medimmune Limited Therapeutic binding molecules
WO2022241057A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
BR112023024169A2 (en) 2021-05-18 2024-02-06 Abbott Lab METHODS FOR ASSESSING BRAIN INJURY IN A PEDIATRIC INDIVIDUAL
AU2022276189A1 (en) 2021-05-20 2024-01-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CA3222291A1 (en) 2021-06-14 2022-12-22 Jaime MARINO Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
AU2022308201A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023281466A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
WO2023012111A2 (en) 2021-08-02 2023-02-09 Basf Se Novel production of aroma compounds with ionylideneethane synthases
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
WO2023028186A1 (en) 2021-08-27 2023-03-02 Abbott Laboratories Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
US20230213536A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
TW202348252A (en) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 Combination therapies for treatment of cancer with therapeutic binding molecules
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4321365A (en) * 1977-10-19 1982-03-23 Research Corporation Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4293652A (en) * 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
US4271145A (en) * 1979-10-22 1981-06-02 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4879219A (en) * 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4362867A (en) * 1980-12-10 1982-12-07 Research Corporation Recombinant cDNA construction method and hybrid nucleotides useful in cloning
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4490358A (en) * 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
USRE32833E (en) * 1982-03-01 1989-01-17 President And Fellows Of Harvard College Screening vaccines and immunization process
US4366264A (en) 1982-04-16 1982-12-28 Stanley Wawzonek Use of calcium metasilicate (wollastonite) as a formaldehyde suppressant for urea formaldehyde resins
DE3303173A1 (en) * 1982-12-13 1984-08-02 Christian Dipl.-Ing. 8900 Augsburg Strobel Method of genetic analysis and synthesis
DE3300632A1 (en) * 1982-12-13 1984-07-12 Christian Dipl.-Ing. 8900 Augsburg Strobel Method of genetic analysis and synthesis
DE3246071A1 (en) * 1982-12-13 1984-06-14 Christian Dipl.-Ing. 8900 Augsburg Strobel Method of genetic analysis and synthesis
US4634678A (en) * 1982-12-13 1987-01-06 Molecular Genetics Research And Development Limited Partnership Plasmid cloning and expression vectors for use in microorganisms
US4719179A (en) * 1984-11-30 1988-01-12 Pharmacia P-L Biochemicals, Inc. Six base oligonucleotide linkers and methods for their use
US4959312A (en) * 1985-05-31 1990-09-25 The University Of Tennessee Research Corporation Full spectrum mutagenesis
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems

Also Published As

Publication number Publication date
EP0590689A2 (en) 1994-04-06
US5814476A (en) 1998-09-29
US5817483A (en) 1998-10-06
AU4434585A (en) 1986-10-23
EP0590689A3 (en) 1994-04-20
JPH0856667A (en) 1996-03-05
JP2584613B2 (en) 1997-02-26
DE3590766C2 (en) 1991-01-10
EP1186660A2 (en) 2002-03-13
FR2579618B1 (en) 1987-12-24
GB2183661A (en) 1987-06-10
EP0229046B1 (en) 1994-05-04
US5824514A (en) 1998-10-20
DE3588239T2 (en) 2003-01-02
US20040161816A1 (en) 2004-08-19
EP0590689B2 (en) 2006-08-16
US6569641B1 (en) 2003-05-27
FR2579618A1 (en) 1986-10-03
HK20292A (en) 1992-03-27
DE3588239T3 (en) 2007-03-08
DE3546806C2 (en) 1991-03-28
DE3588239D1 (en) 2002-06-27
EP1186660A3 (en) 2002-03-20
DE3587814D1 (en) 1994-06-09
US5976862A (en) 1999-11-02
GB2183661B (en) 1989-06-28
CH0229046H1 (en) 1998-07-15
EP0590689B1 (en) 2002-05-22
JPS62502235A (en) 1987-09-03
SG7992G (en) 1992-03-20
JP2004089197A (en) 2004-03-25
WO1986005803A1 (en) 1986-10-09
IN165561B (en) 1989-11-18
JP2002325594A (en) 2002-11-12
US5723323A (en) 1998-03-03
GB8628313D0 (en) 1986-12-31
DE3546807C2 (en) 1991-03-28
IN169027B (en) 1991-08-17
DE3590766T (en) 1987-04-23
DE229046T1 (en) 1987-12-17
CN86102090A (en) 1986-11-05
EP0229046A1 (en) 1987-07-22
CA1339937C (en) 1998-06-30
DE3587814T2 (en) 1994-11-10

Similar Documents

Publication Publication Date Title
CA1341595C (en) Procedure for obtaining dna, rna, peptides, polypeptides, or proteins byrecombinant dna techniques
US5763192A (en) Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
SU1644720A3 (en) Method for preparing antigen determinant of aids virus
US5750344A (en) Method for selection of biologically active peptide sequences
CN112209995B (en) Preparation method of SARS-CoV-2 surface protein receptor binding region
AU699568B2 (en) A method for identification of biologically active peptides and nucleic acids
EP1220933B1 (en) Purification of recombinant proteins fused to multiple epitopes
Panganiban Retroviral gag gene amber codon suppression is caused by an intrinsic cis-acting component of the viral mRNA
Clarke et al. pPV: a novel IRES-containing vector to facilitate plasmid immunization and antibody response characterization
US20030082514A1 (en) Method for identification of biologically active peptides and nucleic acids
EP0109428A1 (en) Cloning vector with indicator genes which have been inactivated by frameshift.
JPH07163379A (en) Method for searching dna fragment coding signal sequence pepetide and vector therefor
KR920007684B1 (en) New expression vectors
JP3335189B2 (en) Region-directed mutagenesis
CN117567642A (en) Recombinant fusion protein and preparation thereof
CN117384864A (en) Recombinant adenovirus for expressing SARS-CoV-2Omicron Spike protein and its application
CN116970632A (en) Recombinant plasmid for expressing SARS-CoV-2S protein, its construction method and application
US6946247B1 (en) RNAse probe protection assays in screening for modulators of immunoglobulin germline transcription
US20040241684A1 (en) Directed protein modification by iterative sequence insertion
MCGRAW MOLECULAR STUDIES OF BACTERIOPHAGE-PHI6: NUCLEOTIDE SEQUENCE OF SEGMENT S (TRANSLATIONAL-COUPLING)